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Abstract 
 
Alpha-synuclein (aSyn) is a pre-synaptic protein linked to Parkinson’s disease (PD) both by 
genetic and pathological evidence. The gene encoding for aSyn was the first to be associated 
with familial forms of PD. In concert, aSyn was identified as the main component of Lewy 
Bodies (LBs), one of the pathological hallmarks of PD along with the loss of dopaminergic 
neurons from the substantia nigra. The discovery that the same protein –aSyn- and its 
aggregation propensity were involved in the pathogenesis of both sporadic and genetic PD 
cases propelled the aSyn research field. Remarkably, further findings characterize a range of 
diseases with parkinsonian features and presenting aSyn aggregates, the so-called 
synucleinopathies. These include amongst others PD, Parkinsons’s disease with dementia, 
dementia with Lewy Bodies (LBs), and Multiple System Athrophy (MSA). Nonetheless, the exact 
mechanisms responsible for aSyn aggregation and toxicity still remain unknown. Try to 
understand the molecular pathways behind aSyn misfolding properties is crucial to shed light 
into the neurodegeneration process, and in the search for therapeutic treatments that may 
alleviate the social burden of PD and related diseases. 
This thesis focuses on the study of the role of aSyn phosphorylation, a post-translational 
modification (PTM) that was shown to be essential in modulating aSyn function, aggregation 
and toxicity. aSyn is indeed phosphorylated on serine 129 (Ser-129) in physiological conditions, 
phosphorylation that goes awry during the pathogenesis of the disease resulting in 90% of aSyn 
phosphorylated in the LBs of brain from patients and transgenic animals models of PD. The 
importance of this modification became soon specific since antibodies used against this residue 
were adopted as common staining procedure for LBs structures. Recently, other 
phosphorylation sites have received intense attention; in particular tyrosine 125 (Tyr-125) 
phosphorylation levels were shown to be significantly reduced in diseased brains.  
Despite the great effort to discover the kinases mediating aSyn phosphorylation; the 
contribution of this modification to aSyn toxicity and aggregation remains elusive. This is 
primarily due to the usage of several different methodological approaches, the difficulty to study 
in vivo such a rapid and reversible modification and the absence of phosphorylation mutants’ 
forms that can properly mimic the effect of this PTM. 
For these reasons, the purpose of this thesis was to investigate the pathways involved in aSyn 
phosphorylation using a simple, effective and well-established model for neurodegenerative 
diseases: the yeast Saccharomyces cerevisiae. This model has been extensively used to 
identify several pathways involved in PD and to generate a consistent model for aSyn 
aggregation that mimics the disease one. Therefore, we took advantage of the power of yeast to 
investigate the effects of aSyn phosphorylation on Ser-129 co-expressing human aSyn and 
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known kinases able to phosphorylate it; namely the Polo-like kinases family (PLKs). We studied 
aSyn inclusions formation and toxicity and we then proceeded to validate the results in 
established mammalian cell model of PD. Our approach demonstrated a unique role for one of 
the member of the kinases family -PLK2- in aSyn inclusion formation. We showed that PLK2 
expression and aSyn phosphorylation on Ser-129 are both required for aSyn inclusion 
formation.  
The role of aSyn Tyr-125 phosphorylation was then studied in an established oligodendroglial 
model of MSA. We demonstrated that this modification can prevent aSyn aggregation 
propensity, but only when phosphorylation on Ser-129 occurred. We then identified novel 
tyrosine kinases inhibitors that may be involved in the disease, but further experimental data will 
elucidate these potential targets.  
Furthermore, using yeast we implemented a functional screening and characterized novel 
kinases, but most importantly, new pathways involved in aSyn pathobiology. ATG1, a kinase 
involved in autophagy, represented one of the major modulator of aSyn aggregation and toxicity 
in yeast; however this novel player requires further validation in mammalian systems to 
establish its potential for therapeutic purposes. 
Altogether, these results provide novel insights and implications for the function of aSyn 
phosphorylation in PD: a co-operative role for serine and tyrosine residue embodies a novel 
clue to unravel aSyn misfolding behavior. Our data represent a unique opportunity to tackle one 
side of aSyn phosphorylation function ad further validate the importance of this PTM in aSyn 
pathobiology. 
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Resumo 
 
A alfa-sinucleina (aSyn) é uma proteína sináptica que está associada à doença de Parkinson 
(DP) segundo evidências genéticas e patológicas. O gene da aSyn foi o primeiro a ser 
associado a casos familiares de DP e a proteína que é codificada foi a primeira a ser 
identificada e como maioritariamente presente nos corpos de Lewy (CL), uma das 
características patológicas da doença. A descoberta de que a aSyn e a sua propensão para 
agregar estão envolvidas não só na patogénese dos casos esporádicos como dos casos 
genéticos estimulou a investigação nesta área. Estudos posteriores identificaram uma série de 
doenças que apresentam várias características parkinsónicas, incluindo a presença de 
agregados de aSyn, e que por isso foram designadas sinucleinopatias. Neste grupo de 
doenças inclui-se a doença de Parkinson com demência, demência com Corpos de Lewy e 
Atrofia de Múltiplos Sistemas (AMS). No entanto, os mecanismos específicos responsáveis 
pela agregação e toxicidade da aSyn ainda estão por desvendar. É crucial entender as vias 
moleculares responsáveis que levam à perda de conformação da aSyn para aprofundar o 
conhecimento sobre o processo de neurodegeneração e encontrar novas terapias que possam 
atenuar o peso soció-económico da DP e doenças relacionadas. 
Esta tese foca-se no estudo do papel da fosforilação da aSyn, uma modificação pós-traducional 
essencial na modulação da função da aSyn, na sua agregação e toxicidade. Em condições 
fisiológicas apenas 4% da aSyn é fosforilada na serina 129 (Ser-129), enquanto que na DP 
90% da aSyn está fosforilada e deposita-se nos CL dos cérebros dos doentes, um mecanismo 
reprodutível em modelos de animais transgénicos da DP. A importância desta modificação 
tornou-se específica dado que têm sido usados como procedimento comum anticorpos contra 
este resíduo para corar os CL. Recentemente, outros locais de fosforilação têm sido alvo de 
estudo, em particular a tirosina 125 (Tir-125), cujos níveis de fosforilação estão particularmente 
reduzidos nos cérebros de doentes.  
Apesar do grande esforço para descobrir as cinases que fosforilam a aSyn, a contribuição 
desta modificação para a sua agregação e toxicidade é ainda desconhecida por várias razões: 
a utilização de métodos experimentais diferentes, o facto de ser uma modificação difícil de 
estudar in vivo dada a rapidez e reversibilidade da fosforilação, e porque não existem mutantes 
que consigam mimetizar convenientemente o efeito desta modificação.  
Por estas razões, o objectivo desta tese é estudar as potenciais vias envolvidas na fosforilação 
da aSyn, usando um modelo simples, eficaz e bem estabelecido para doenças 
neurodegenerativas: a levedura Saccharomyces cerevisiae. Este modelo tem sido usado com 
sucesso na identificação de várias vias envolvidas na DP, tais como a disfunção mitocondrial e 
do proteassoma e, surpreendentemente a formação de inclusões de aSyn que mimetizam as 
inclusões observadas na doença. Tirando partido deste modelo caracterizámos o efeito de 
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cinases conhecidas na fosforilação da Ser-129, nomeadamente da família das cinases tipo-
Polo. Caracterizámos a formação de inclusões de aSyn e a sua toxicidade em levedura, e 
posteriormente validámos os resultados em modelos celulares de mamíferos de DP. 
Demonstrámos um papel único da PLK2, um dos membros da família das cinases tipo Polo, 
quanto à formação de inclusões de aSyn. Verificámos que a expressão de PLK2 e a 
fosforilação de aSyn são necessários para a formação de inclusões de aSyn.   
O papel da fosforilação da Tir-125 foi estudado num modelo celular já estabelecido de AMS em 
oligodendrócitos. Nós demonstrámos que esta modificação pode prevenir a propensão da aSyn 
para agregar, mas apenas quando a fosforilação na Ser-129 ocorre simultaneamente. 
Posteriormente identificámos novos inibidores de cinases de tirosinas que podem estar 
envolvidas na doença, mas mais estudos são necessários para identificar estes potenciais 
alvos.  
Além disso, implementámos um screening funcional nas leveduras e caracterizámos novas 
cinases e novas vias envolvidas na patobiologia da aSyn. A cinase com maior efeito na 
modulação da agregação e toxicidade da aSyn foi a Atg1 que está envolvida na autofagia. É 
necessário validar o papel desta cinase em sistemas de mamíferos para estabelecer o seu 
potencial terapêutico.  
Em resumo, estes resultados proporcionam novos conhecimentos e implicações para a função 
da fosforilação da aSyn na DP: um papel conjunto da fosforilação na serina e tirosina que 
aponta uma nova pista para desvendar a perda de conformação da aSyn. Os nossos 
resultados representam uma oportunidade única para estudar a função da fosforilação e por 
outro lado validar a importância desta modificação pos-traducional na patobiologia da aSyn.  
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1. Introduction 
 
1.1. Synucleinopathies 
 
In 1997 alpha-synuclein (aSyn) was identified as one of the main proteins present in Lewy 
Bodies (LB), one of the pathological hallmarks of Parkinson’s disease (PD) 1. Abnormal 
depositions of fibrillar aSyn characterized a group of diverse disorders collectively called 
synucleinopathies 2. The most common aSyn disorders include PD, Parkinsons’s disease with 
dementia (PDD), dementia with Lewy Bodies (DLB), Multiple System Athrophy (MSA) and 
Neurodegeneration with brain iron accumulation type I (NBIA) 3, 4. 
Although synucleinopathies are characterized by the deposition of filamentous aSyn 
aggregates, what permits distinguishing among these disorders is the localization of aSyn 
depositions and their ultrastructure 5, 6. The three main aSyn pathological depositions found in 
these disorders are: LBs, Lewy neurites (LNs) and glial cytoplasmic inclusions (GCIs) (Fig .1).  
LBs mainly deposed in the substantia nigra of the brain, but as the disease progresses, they 
are also found in other areas such as the limbic system, the olfactory bulb and the neocortex. 
Some studies proposed that LBs pathology starts in the lower brainstem and olfactory bulb with 
the substantia nigra only affected in the middle stage of the disease, suggesting a staging 
progressive disease pattern with aSyn pathobiology sequentially spreading throughout the 
brain: the so-called Braak stages of the disease 7, 8. Inclusion bodies have a globular/spherical 
structure in the cytoplasm and perinuclear compartment (LBs), and spindle-like in the cellular 
processes (Lewy neurites) (Fig. 1). Ultrastructurally, LBs form eosinophilic inclusions, between 
5-25 μm in size, composed of a halo of straight fibrils and a dense granular core 5. LBs mainly 
consist of aSyn phosphorylated on Ser-129 1, 9, but numerous others proteins were described 
to deposit in LBs 10, such as ubiquitin 11, neurofilaments 12 and synphilin-1 13. Remarkably, LBs 
are present only in surviving neurons, thus their formation may represent a protective 
mechanism used by neuronal cells to disarmed harmful misfolded proteins 14. 
Glial cytoplasmic inclusions (GCIs) can have triangular, sickle, half-moon, oval, or conical 
shape. Immunostaining analysis revealed a major protein component represented by aSyn. As 
for LBs aSyn is phosphorylated on Ser-129, and several other proteins co-deposited with it, 
such as ubiquitin, tubulin, and synphilin-115. Ultrastructurally, GCIs consist of randomly 
arranged, tightly packed, granule-coated filaments, similar to the LBs ones, which are 10-20 
μm in diameter. GCIs are predominately found in oligodendrocytes with few neuronal inclusions 
that can be easily differentiated from LBs due to their intra-nuclear localization 15 (Fig. 1). GCIs 
are widespread in the nervous system, although a higher density can be seen in motor cortical 
area, caudate nucleus, putamen, globus pallidus, cerebellar white matter and in the olfactory 
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bulbs. aSyn deposits are also found in another set of disorders: sporadic and familial 
Alzheimer’s disease (AD), Down’s syndrome, taupathies such as Guam parkinsonian–
dementia complex, Gaucher disease and other lysosomal storage disorders and motor neuron 
diseases 6. In these disorders aSyn pathobiology is considered secondary to the main 
pathological process. To date, some patients can present the same clinical features 
characterizing synucleinopathies but without aSyn deposition. 
 
 
Figure 1. Microscopic findings in PD (on the left) and MSA (on the right) with aSyn 
immunohistochemistry. On the left panel: A. typical brainstem Lewy Body (LB), B. staining of a 
cortical Lewy Body (LB). On the right panel: A. Glial cytoplasmic inclusions (GCIs) in the putamen, B. 
neuronal cytoplasmic inclusion (NCI) in pontine nuclei (arrow). Adapted from 
16
. 
 
 
1.2. Parkinson’s disease 
 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder 
characterized by degeneration of dopaminergic neurons from the substantia nigra in the brain 
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and affecting approximately 1% of the population older than 60 years 17. The majority of PD 
cases are sporadic, while only about 5% of them are known to have dominantly or recessively 
inherited forms that arise from specific genes. Clinically patients display bradykinesia (slowness 
of the movement), rigidity, resting tremor and postural instability (Fig. 2). Two are the main 
pathological hallmarks of the disease: intracellular proteinaceous inclusions named LBs and 
loss of dopaminergic neurons in the substantia nigra pars compacta (Fig. 2) 18.  LBs are 
characterized by the deposit of misfolded proteins and they are mainly composed of aSyn and 
ubiquitin. The biochemical nature of these deposits remained unknown until 1997 when aSyn 
was found to be their main component 1. The original idea came from a previous study, where 
a genetic mutation in aSyn gene (SNCA) caused a familiar form of the disease 19. These 
studies indicated for the first time that the same protein might be involved in both the sporadic 
and genetic cases of PD 1, 5, 20.  
The symptoms appear in chronological order, with non-motor signs manifesting prior to motor 
ones. Subtle neuropsychological problems can be visible early in the course of PD, but there 
are not commonly assessed by clinicians. They involved problem-solving strategies, attention 
capacities and decision making. They manifest in difficulties with everyday activities such as 
organizing medications and paying bills. Memory deficits are mainly detected with further 
progression of the disease 21. Autonomic dysfunctions are then described: orthostatic 
hypotension, constipation, insomnia, urinary frequency and urgency and sweating 
abnormalities 22. Particularly, olfactory deficits may represent an early sign of PD, although 
research findings are not consistent 23, 24. 
Neuropsychiatric symptoms are prevalent in the late stages of the disease. The most common 
observed are depression, anxiety, apathy and irritability, with the majority of patients displaying 
at least one of these symptoms 25. Motor dysfunction manifest only after extensive 
dopaminergic neuron loss, suggesting the presence of a compensatory mechanism in the early 
stages of the disease that can counteract the progressive neurodegeneration 26. An attributable 
cause for PD is still unknown but both environmental and genetics factors are believed to 
contribute to its pathogenesis. In PD sporadic cases several environmental risk factors have 
been identified: exposure to heavy metals such as manganese, copper, pesticides or brain 
injury might increase the risk to develop PD 17, 27, 28. A specific case referred back to 1982, 
when several drug users experienced Parkinsonism symptoms while using a drug: 1-methyl-4-
phenyl-4-proprionoxy-piperidine (MPPP). A side product, MPTP, derived by its synthesis was 
shown to be converted into MPP+ by dopaminergic neurons using endogenous enzymes: 
monoamine oxidase-B (MAO-B) 29. This bio-product was able to impair the complex I of the 
mitochondrial chain, generating reactive oxygen species (ROS), implicated in PD pathogenesis 
30. 
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Figure 2. Clinical and pathological features of Parkinson’s disease. On the left panel the major 
clinical manifestations in PD patients. On the right panel the selective death of dopaminergic neurons 
in the substantia nigra of PD patients (www.adam.com). 
 
 
1.2.1. Genetics of Parkinson’s disease 
 
It is firmly believed that PD is determined by both multiple genetic and environmental 
factors; nonetheless numerous gene mutations have been correlated to autosomal 
dominant or recessive PD cases, counting for 5% of the total 31, 32. Two of the genes 
responsible for autosomal dominant inherited cases of PD are the SNCA gene encoding 
aSyn 19 and Leucine-rich repeat kinase 2 (LRRK2) 33. Autosomal recessive cases involved 
genes for PRKN (Parkin) 34, PINK-135 and DJ-1 36 (for a complete list of genes associated 
with familial forms of PD see Table 1). Remarkably, all genetic forms present aSyn 
pathobiology; except for some cases carrying PRKN mutation and rarely LRRK2 mutation. 
Investigators also defined polymorphisms as risk factor for PD: carriers of a single 
Glucocerebrosidase (GBA) mutant allele have five time higher risk for PD 37 as well as at 
the SNCA gene promoter (detailed in paragraph 1.2.2). Recently, genome-wide studies 
have propelled the discovery of novel genes associated with PD; amongst them data 
showed consistent association with SNCA and microtubule-associated protein Tau (MAPT) 
loci 38, 39. 
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 Table 1. Genes linked with familial forms of PD. (AD=autosomal dominat; AR= 
autosomal recessive; UR=unknown relevance). 
Locus Gene Protein Inheritance 
PARK1/PARK4 SNCA Alpha-synuclein AD 
PARK2 PARK2 Parkin AR 
PARK3  SPR(?) (?) AD (not 
validated) 
PARK6 PINK1 Pten-induced kinase 1 AR 
PARK7 PARK7 DJ1 AR 
PARK8 LRRK2 Leucine-rich repeat 
kinase 2 
AD 
PARK9 ATP13A2 ATPase type 13A2 AR 
PARK10 PARK10 (?) UR 
PARK11 GIGYF2 (?) GRB10 interacting 
GYF protein 2 
AR 
PARK12 PARK12 (?) UR 
PARK13 Omi/HTRA2 HtrA serine peptidase 
2 
UR 
PARK14 PLA2G6 Phospholipase A2, 
group VI 
AR 
PARK15 FBX07 F-box protein 7 AR 
PARK16 PARK16 (?) UR 
PARK17 VPS35 Vacuolar protein 
sorting 35 
Homolog 
AD 
PARK18 EIF4G1 Eukaryotic translation 
initiation factor 4 
gamma, 1 
AD (not 
validated) 
 
aSyn (SNCA) was the first identified gene to cause dominantly inherited PD when, in 1996, 
a point mutation leading to the substitution A53T was described in Italian and Greek 
families. Subsequently, two other point mutations were discovered: A30P 40 and E46K 41. 
Moreover, duplication and triplication of the gene locus were reported 42-44, with 50% 
increase in gene dosage for duplication generating idiopathic PD, while 100% increase 
producing a more severe phenotype with dementia 45. aSyn protein expression correlated 
with the number of gene copies, demonstrating a link between aSyn expression levels, 
disease progression and severity 46. Polymorphisms in the promoter region of SNCA gene 
were also identified 47. An imperfect dinucleotide repeat called REP1 presents allele-length 
variability and shows association of individuals with 263 base pair allele-length with higher 
risk for PD. Interestingly, this polymorphism increases three times aSyn expression levels 
48. aSyn coding exons, particularly 5 and 6, demonstrated also genetic variability correlated 
with augmented predisposition for PD 49. 
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1.2.2. Pathophysiology of Parkinson’s disease 
 
The primary neuropathological deficit in PD is the loss of dopaminergic neurons in the 
substantia nigra pars compacta portion of the basal ganglia accompanied by LBs formation 
–inclusions enriched in aSyn and ubiquitin- in surviving neurons. The classic 
depigmentation of the basal ganglia area, visible in post-mortem PD brain, correlates with 
depletion of the neurotransmitter dopamine in the putamen (corpum striatum), primary site 
of substantia nigra neuronal projections. In a healthy individual dopamine is released from 
substantia nigra pre-synaptic terminals to the extracellular space where it will bind and 
activate two main dopamine transporters called D1 and D2. Neurodegeneration of the 
substantia nigra neurons impaired the dopamine release, decreased the nervous input to 
the striatum region, ultimately leading to the motor manifestations characteristic of PD. 
Remarkably, the neuronal changes occurring in PD, are also found in other brain systems 
such as serotonergic and cholinergic ones, as well as in the cortex, olfactory bulbs, and the 
autonomic nervous system. 
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Figure 3. Intracellular pathways implicated in Parkinson’s disease pathogenesis. Several 
factors may play a role in aSyn pathobiology: missense mutations and genomic multiplications of 
SNCA (the gene encoding aSyn), oxidative stress and C-terminal phosphorylation. All these factors 
have the capacity of increasing aSyn levels and/or promoting aSyn oligomerization and fibrils 
formation. The cell can respond rapidly and degraded misfolded aSyn by ubiquitin–proteasome 
system (UPS) and/or endosomal–lysosomal pathways. Gene mutations that may alter the activity of 
the UPS such as parkin and UCH-L1 can lead to neuronal toxicity. On the other side formation of 
aSyn oligomers, not effectively cleared, can promote their accumulation and induced toxicity by 
inhibiting the proteasome. aSyn genetic mutations can instead impair its vesicular binding, altering 
the vesicle trafficking. Similarly, aSyn can disrupt dopamine production (inhibition of tyrosine 
hydroxylase), packaging and vesicle dynamics, thus impairing dopamine release and promoting its 
accumulation in the cytoplasm ultimately generating ROS. Parkin and DJ-1 mutants can alter the 
proteasome function impairing aSyn clearance. Furthermore, proteasome function requiring ATP 
synthesis by mitochondria, mutation of PTEN-induced kinase 1 (PINK1), DJ-1 and parkin can 
compromise normal mitochondrial function resulting in early-onset Parkinsonism. Leucine-rich repeat 
kinase 2 (LRRK2) instead can play a role in cellular trafficking and intracellular signaling modulating 
aSyn aggregation state 
50
. 
 
. 
It is generally believed that aSyn promotes the neurodegenerative process through a toxic 
gain-of-function. Triggering events involved: aSyn gene duplication/triplication or promoter 
polymorphisms that lead to increase protein levels 51; gene mutations or oxidative stress 
that promotes aSyn misfolding behavior with formation of toxic oligomeric species 52, 53; and 
cell degradation system malfunctioning, which enhances aSyn accumulation and ultimately 
LBs deposition 54 . 
The effects produced by this toxic gain-of-function are expressed mainly at the synapses 
where neurotransmitters release is decreased. The SNARE protein complex (the machinery 
for vesicle release) is re-distributed and synaptic vesicles’ recycling is inhibited 55-58. It is 
believed that aSyn oligomers play an important role in this scenario, they may be able to 
generate membrane pores that can alters the calcium voltage-gated channels and disrupt 
calcium homeostasis 59-61 and/or induce leakage of dopamine at vesicles membranes, 
which is known to contribute to the production of ROS 62. 
Oxidative stress in particular, can be triggered by several factors: mitochondrial aSyn over-
expression and/or mutation can disrupt the complex I of the respiratory chain 63-65; aSyn 
oligomers can induce mitochondria malfunction or morphological changes 66-68; aSyn gene 
mutations or genes know to be associated with PD, such as DJ-1 69, 70 can alter 
mitochondria morphology and stimulate mitochondrial autophagy; or environmental 
mitochondrial toxins (a known risk factor) can induce mitochondria dysfunction. 
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Furthermore, mutations in parkin and PINK1 can cause mitochondrial deficit and 
accumulation of ROS and dopamine metabolites. 
A crucial factor in aSyn mediated toxicity -discovered in yeast- is the ER-to-Golgi trafficking 
impairment, comprising in particular Rab1, a protein involved in this transition 71. The delay 
in the ER to Golgi transition arises from aSyn re-distribution at the SNARE complex 72, 
corroborating aSyn function and interaction with the synaptic vesicular system 73. 
The formation of aSyn aggregates can be modulated by other gene mutations also 
associated with PD, such as LRRK2. LRRK2 co-expression with aSyn promotes aggregate 
formation, phosphorylation, and aSyn release into the extracellular media 74. 
aSyn genetic mutants are also able to induce proteasome dysfunction in several cell 
cultures and in vivo systems 75-78, and it is thought that oligomeric aSyn species exert this 
effect 79, 80. aSyn mutants can also impair chaperone mediated autophagy (CMA) 81-83, 
although this is still controversial. However, impairment of the degradation system could 
reinforce the formation of aSyn oligomeric species, aggregates formation and LBs 
formation.  
aSyn can interact with chaperones protein such as: Hsp27, Hsp70, and Hsp90 84. 
Overexpression of Hsp27 can reduce aSyn mediated toxicity; Hsp70 was shown to inhibit 
aSyn fibrils binding to aSyn oligomers 85; and carboxyl terminus of Hsp70-interacting protein 
(CHIP) can co-localize with aSyn in LB and decrease aSyn fibrillization 86. Furthermore, 
CHIP can ubiquitinate aSyn 87 and direct it for degradation via the proteasome and the 
lysosome pathways 86. 
 
A recent finding has generated great attention within the PD research field. aSyn, mostly 
considered an intracytoplasmic protein, it was detected in plasma, saliva and cerebro-spinal 
fluid (CSF) 88, 89, offering the evidence for aSyn potential secretion. It is not clear how aSyn 
secretion occurs, but it seems to take place through a non-classical secretory pathway. In 
SH-SY5Ycells aSyn can be released via exosomal vesicles whose function is dependent on 
calcium influx 90. Secretion of both aSyn monomers and fibrils was also observed in cell 
cultures as a result of proteasome impairment or mitochondrial dysfunction 89. aSyn release 
through exosomes was further confirmed in SH-SY5Y cells that present, interestingly, 
lysosomal dysfunction. This perturbation also produced an increase in aSyn cell to cell 
transmission and formation of insoluble aggregates 91. Remarkably, extracellular secreted 
aSyn, especially oligomeric forms, can influence the surrounding environment leading to 
cell death 90, 92. aSyn can be uptaken by neighboring cells via endocytosis, here aSyn 
aggregates, but not monomers, are then directed to the lysososmal compartment for 
degradation, reflecting a possible protective mechanism 93. Conversely, other studies 
demonstrated that aSyn oligomeric species, after being uptaken, can seed fibrillization of 
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endogenous aSyn 60, 94-97. Significant in vivo studies validated aSyn cell to cell transmission 
and spreading hypothesis: progenitor cells implanted in the hippocampus of aSyn 
transgenic mice were able to incorporate aSyn 98, 99; and fetal dopaminergic grafts in 
humans showed LB pathology years after implantation 100 101. A recent study using WT mice 
has demonstrated that a single striatal injection of aSyn fibrils produced aSyn intracellular 
transmission throughout the brain, reducing dopamine levels and generating motor 
symptoms PD-like 102. Remarkably, LB-like inclusions with aSyn highly phosphorylated 
were detected and a spreading mechanism dependent on neuronal connectivity was 
demonstrated. 
This phenomenon represents a potential explanation of aSyn propagation, according to 
Braak’s staging hypothesis 8 and the possibility that aSyn may indeed act as a prion-like 
protein. aSyn staining in a series of PD patients and age-matched controls suggested that 
Lewy pathology evolves in a sequential and recognizable manner, starting in the olfactory 
system, peripheral autonomic nervous system, and dorsal motor nucleus of the vagus; then 
proceeding to the dopaminergic neurons of the substantia nigra only in the middle stage of 
the disease and only at later stage to the cortex layers 7 (Fig 4).  These sequential 
processes firmly address the possibility that Lewy pathology can spread from affected to 
unaffected regions in a prion-like manner. 
It is clear that many different factors can play a prominent role in aSyn toxicity, particularly 
which one initiates the pathological cascade; nonetheless each cellular process needs to be 
properly evaluated to unravel aSyn abberant behavior. 
 
 
Figure 4. Distribution and progression of Lewy Body pathology according to 
7, 103
. The 
gradual decrease in red shading intensity represents the topographical expansion of the lesions 
during the course of the disease. Pathology initially occurs in the dorsal motor nucleus and 
frequently in the anterior olfactory nucleus, then expands gradually into related areas as the brain 
stem (white arrows) taking an upward direction (white arrows).  
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1.2.3. Animal models of Parkinson’s disease 
 
Animal models are a necessary tool in the study of PD pathogenesis and progression, since 
research on neurodegenerative diseases requires the presence of a complex nervous 
system to unravel the affected biological processes. However, an animal model that fully 
recapitulates all the key features of the disease has still to be developed. The ideal model 
should be age-dependent, progressive and accompanied by dopaminergic loss 104, in 
addition to present motor symptoms, neurodegeneration dopamine reversible and  LBs and 
LNs 105. 
1.2.3.1. Neurotoxin models 
 
1.2.3.1.1. 6-Hydroxydopamine (6-OHDA) 
 
6-OHDA is a hydroxylated analogous of dopamine (DA) that uses DA transporter to 
reach the cytosol where it is oxidized, generates ROS and ultimately leads to 
oxidative stress 106, 107. Here, it also inhibits the complex I and IV of the mitochondrial 
respiratory chain 108, 109.  
As a well-established model of PD, it is injected stereotactically in the rat brain 110, 
because it cannot pass the blood-brain-barrier (BBB). Unilateral injection is 
preferred because bilateral injection often results in adipsia, aphagia, and death. 
Several studies inject 6-OHDA into the striatum to see retrograde degeneration, 
because the progressive and less extensive lesion is more relevant to PD, and 
furthermore, synaptic terminals have been shown to die prior to subtantia nigra 
neurons 111. 6-OHDA treatment produces the loss of more than 80% of nigrostriatal 
neurons 109, 112 and motor impairment 113, 114. Notably, it has been shown to produce 
non-motor symptoms of PD, including cognitive and gastrointestinal dysfunction 115, 
116. The major drawbacks are the absence of LB inclusions and no phenotype age-
dependecy. 
The 6-OHDA model does not involve aSyn pathobiology, although it was shown to 
interact with aSyn 117, therefore it is primarily used as preclinical model to assess 
pharmacological therapies 118, 119. 
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1.2.3.1.2. MPTP 
 
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model dates back to the 
early 1980s when several Californian drug users showed symptoms similar to PD 29, 
120. These patients had self-administered synthetic desmethylprodine (MPPP) 
contaminated with MPTP 29. Successful treatment with L-DOPA and post- mortem 
analysis demonstrating loss of nigrostratial connections, improved the knowledge on 
PD and the molecular mechanisms behind the disease 120, 121.  
MPTP is lipophilic thus can easily cross the BBB. It is subsequently uptaken by 
astrocytes and metabolized to MPP+ by monoamine oxidase-B (MAO-B). MPP+ is a 
toxic molecule uptaken by dopaminergic neurons through dopamine transporter 122, 
123 where interacts with the complex I of the mitochondria respiratory chain 
generating ROS 124. MPTP primarily damages the nigrostriatal dopaminergic 
neurons 122, 125, 126.  
The toxin is administered to animals by stereotactical, intravenous or intraperitoneal 
injection 109. Non-human primates treated with MPTP showed aSyn positive LB-like 
structures and presented similar clinical, pathological and pharmacological response 
as idiopathic PD 127, 128. LBs formation remains controversial, although described in 
monkeys, it is not present in mice unless chronically exposed over 30 days at low 
doses, while rats are resistant to the toxin. MPTP monkey model is mainly used to 
distinguish behavioral and symptomatic components of PD, whereas mouse to study 
the neuronal death process, and as an initial screening tool to test potential 
treatments for PD 129. Anyway, MPTP represent the most used toxin based animal 
model of PD due to its ability to produce PD-like effects in humans and non-human 
primates, its reproducible nigrostriatal system lesions, and its easy routes of 
administration. 
 
 
1.2.3.1.3. Paraquat and Rotenone 
 
Once MPTP was described as a potential molecule to model PD pathophysiology, 
similar compounds started to be screened. The herbicide paraquat (N,N’-dimethyl-4-
4’-bipiridinium) was identified in 1985 130; paraquat seems able to pass the BBB 
using the neutral amino acid transporter 131, 132, accumulates in the brain age-
dependently, but it is still unknown how enters the dopaminergic neurons.  
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Toxicity is mediated by generation of superoxide 133, although the damage induced 
in the dopaminergic system has not been consistently observed 134, 135. Systemic 
injection can be used to induce motor deficits and loss of dopaminergic neurons in a 
dose- and age-dependent manner 136-138. Its treatment generates aSyn aggregates 
that resemble LBs in PD 139, 140. Although epidemiological studies suggested an 
increased risk for PD after paraquat exposure 141-143, the lack of significant effect on 
striatal dopamine depletion limits the use of this model for neuroprotection studies. 
Rotenone is a widely used pesticide, highly lipophilic that can cross the BBB and act 
on the complex I of the mitochondrial respiratory chain. The rotenone model was 
only implemented in 2000 developing a chronic low-dose treatment 144. Infused 
continuously, rotenone produced selective nigrostriatal neurodegeneration and aSyn 
cytoplasmic inclusions. This study suggests that a chronic low-dose treatment may 
be required to produce LBs, a feature difficult to reproduce in other toxin-based 
animal models 145. Rotenone can also be inhaled, subcutaneously injected or orally 
delivered 146. Remarkably, in rats, motor dysfunctions and dopaminergic cell loss 
were reversed by L-DOPA treatment 144, 147, 148 and toxicity affected other neuronal 
systems as described in PD 149. The rotenone infusion model, despite its positive 
features, has not been generally adopted; this is mainly due to the inability to 
reproduce consistently the parkinsonian phenotype 150-152. 
 
 
1.2.3.2. Genetic models 
 
1.2.3.2.1. Animal models 
The number of genetic models based on PD associated genes is enormous and far 
from the purpose of this thesis, therefore only the principal findings will be 
summarized.  
aSyn genetic models are much influenced by the promoter used to induce aSyn 
expression 104. Under Thy-1 promoter, aSyn is highly expressed in the substantia 
nigra; in some mice motor impairment is present as well as inclusion bodies, the 
latter not resembling LBs 153. The Prion (Prp) promoter induced instead a 
widespread aSyn expression but, mostly, not consistent with PD pathology 154. Only 
the transgenic for aSyn A53T genetic mutation showed aSyn aggregation and age-
dependent neurodegeneration 155, 156.  Tyrosine hydroxylase promoter (TH) directs 
aSyn expression exclusively in the dopaminergic neurons, but only double mutants 
for A53T and A30P aSyn genetic mutants showed loss of dopaminergic neurons, 
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motor impairment and decreased in dopamine levels age-dependent without protein 
inclusions 157. One reason of the failure of these models may reside in Syn 
fibrillization propensity; indeed little amounts of mouse aSyn are able to inhibit 
human aSyn fibrillizzation in vitro 158. A conditional transgenic mouse was recently 
generated using aSyn under a tetracycline promoter, although it failed to show aSyn 
aggregation, displayed dopaminergic cell loss and progressive motor impairment 159. 
Interestingly, mice knocked-out (KO) for aSyn did not show alterations in the 
dopaminergic neurons development or maintenance, however they present a 
reduction in striatal dopamine and an attenuation of dopamine-dependent motor 
response to amphetamine 160. Remarkably, these mice are also resistant to MPTP 
and other mitochondrial toxins 125, 161. 
Rat models of lentiviruses and adeno-associated viruses are also used to model PD 
pathology. This method allows stereotactical injection of aSyn constructs directly in 
the substantia nigra, even in older animals. Anyway, they require proper handling 
and they may have reproducibility issues. Rats overexpressing aSyn WT or mutants 
showed selective loss of nigral dopaminergic neurons 162 that in adult animals was 
accompanied by aSyn positive inclusions 162-164. Recently, human aSyn bacterial 
artificial chromosome constructs (BAC) have been used in rats, here aSyn 
expression showed prominent coversion to C-terminally truncated form. In old 
animals aSyn was converted into insoluble fibrils, resembling PD ones, and the 
animals suffered severe loss of the dopaminergic projections 165.  
In Drosophila models, over-expression of aSyn WT, A53T and A30P mutations 
develop motor deficits, loss of dopaminergic neurons age-dependent and inclusions 
formation 166. C. elegans models over-expressing aSyn showed dopaminergic 
neuron loss but no LB-like inclusions 167, 168. The effect of aSyn mutations on 
dopaminergic neurons did not show major differences compared to aSyn WT. 
Although flies and nematode models lack of endogenous aSyn, their use allowed 
the discovery of numerous genes and pharmacological modifiers of aSyn toxicity. 
Both fly, nematode and mouse models demonstrated an increase in aSyn toxicity in 
presence of rotenone and 6-OHDA 169, corroborating environmental factors as risk 
for PD. 
Saccharomyces cerevisiae - another powerful model to study aSyn pathobiology - 
for the purpose of this thesis will be described in details in section 1.6.  
LRRK2 mutations are associated with dominant inherited form of PD: 
overexpression of LRRK2 in Drosophila and C. elegans leads to degeneration of 
dopaminergic neurons 170-172. Mice KO for LRRK2 did not display any toxicity related 
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to neuronal dopaminergic development and maintenance 173, while several LRRK2 
mouse models showed only low levels of neurodegeneration 174.  
Mutations to parkin, DJ1 and PINK1 cause autosomal recessive forms of PD. 
Drosophila models displayed age-dependent loss of dopaminergic neurons and 
locomotors abnormalities, whereas the mice models failed to replicate many key 
features of PD. KO rodent models of these genes did not show nigrostriatal 
degeneration, or cytoplasmic inclusions that resembles PD cases, except for PINK1 
KO mice showing reduced dopamine release in the striatum 175. However, recently 
KO parkin in old mice generated neurodegeneration in the substantia nigra 176. 
 
 
1.2.3.2.2. In vitro models 
The number of in vitro models of PD is broad, therefore, for the purpose of this 
thesis, only the principal mammalian cell models will be described. 
The expression of solely aSyn in several cell models does not induce cytoplasmic 
inclusions or strong cytotoxicity, thus other methods started to be employed, such as 
protein overexpression or toxin-based. Neuronal cells over-expressing aSyn were 
shown to form cytoplasmic inclusions and presented mitochondrial deficits 177. 
Human neuroblastoma cells expressing aSyn A53T or A30P mutants, exposed to 
hydrogen peroxide or the neurotoxin MPP+ were more vulnerable to oxidative 
stress, particularly the A53T one 178; similar results were obtained using menadione-
induced oxidative stress 179. In another model, neuroblastoma cells over-expressing 
aSyn WT, A53T and A30P mutants showed increased ROS production, more 
pronounced in the mutants. Remarkably, exposure to dopamine decreased cell 
viability, phenomenon further enhanced in the mutants 180. Likewise, only 
accumulation of aSyn in cultured dopaminergic neurons leaded to dopamine 
dependent apoptosis and ROS production 181. 
aSyn A53T or A30P inducible expression in differentiated PC12 showed 
increased sensitivity to apoptotic cell death (while treated with 
proteasome inhibitors), mitochondrial depolarization and elevation of caspase 3 and 
9 76. 
Further methods took advantage of known aSyn binding protein detected in LBs. 
Co-expression of the protein synphilin-1 and aSyn promotes the formation of 
cytoplasmic inclusions 13, 182. The fusion of green fluorescent protein (GFP) to the C-
terminal of aSyn was shown to undergo truncation within the GFP domain and to 
induce aSyn aggregation 183, 184; this aggreagation propensity was further enhanced 
by co-expressing synphilin-1 (Fig. 5).  
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The bimolecular fluorescent complementation assay (BiFC) has demonstrated great 
impact in the study of aSyn oligomers formation. This assay involves the fusion of 
two non-fluorescent fragments of GFP to the proteins of interest. In case an 
interaction occurs between the two proteins of interest, the reporter fragments can 
combine together and reconstitute the activity of GFP 185. Stabilization of aSyn 
oligomers via BiFC in human neuroglioma cell line, increased intracellular toxicity, 
which could only be rescued reducing oligomers formation 186 (Fig. 5). 
Other cellular models relied on aSyn extracellular uptake as seed for the fibrillization 
of the intracellular aSyn 96, 97, 187, 188. Unfortunately cell culture studies showed some 
discrepancies on the effect of aSyn expression and/or mutations on citotoxicity; in 
some, aSyn expression made the cells more sensitive to cellular stress 189, 190, while 
in others was shown to be protective 191, 192. These discrepancies probably arise 
from the use of different cell lines, different promoters or protein tags 193. 
Although the scientific community is still looking for the perfect PD model, the 
studies hereby described have demonstrated to be essential to identify the 
molecular mechanisms (yeast, worms and flies), the biological pathways (cellular 
models) and the behavioral features (animal models) involved in PD pathogenesis 
and aSyn pathobiology.  
 
Figure 5. Schematic representation of aSyn aggregation models. Misfolded aSyn 
monomers may promote the formation of dimers and oligomers that, if failed to be degraded 
by the intracellular protein degradation machinery, can seed aggregation of other aSyn 
monomers leading to fibrils formation and ultimately to LBs proteinaceous inclusions. 
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Several assays are used to characterize which species can be formed at cellular levels: the 
bimolecular fluorescence complementation (BiFC) assay, which depends on formation of a 
fluorescent complex, allows visualization of aSyn dimers and oligomers (green); aggregates 
formation can instead be modelled co-expressing aSyn and synphillin-1 (red), which 
positively react for ThioflavinS staining (green) 
194
. 
 
 
 
1.3. Multiple Systems Atrophy 
 
The term Multiple Systems Atrophy (MSA) was initially used to describe three different 
disorders that had as common feature neuronal atrophy: olivopontocerebellar atrophy 195, 
striatonigral degeneration 196 and Shy-Drager syndrome 197, 198. MSA was included in the 
synucleinopathies group when Papp and colleagues described that glial cytoplasmic inclusions 
(GCIs) –one of the neuropathological hallmarks of these disorders- contained aSyn as main 
component 199.  
MSA is a progressive, sporadic disease, with adult onset (between 55 and 58 years old). 
Clinical hallmarks comprise variable combination of parkinsonism, cerebellar ataxia, autonomic 
dysfunction and/or corticospinal dysfunction 200. MSA motor phenotype is primarily divided into 
patients with predominant parkinsonism (MSA-P) or cerebellar ataxia (MSA-C) 201. The 
heterogeneity of clinical features increases the chances of wrong diagnosis as well as the 
absence of specific biomarkers, thus a definitive validation necessitates of post-mortem 
histopathological analysis. 
The main pathological features comprise: neuronal loss, gliosis, myelin pallor and severe 
axonal degeneration. In addition, between 10 to 32% of MSA patients suffer from cognitive 
dysfunction 202. Reactive astrocytes, containing swollen and intense GCIs, and activated 
microglia are common histological findings in MSA white matter, with astrogliosis paralleling 
the severity of neurodegeneration 203, 204 (Fig. 6).   
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Figure 6. Common histological features of Multiple System Atrophy (MSA). A. Neuronal loss 
(arrowheads) B. gliosis (hypertrophic astrocytes) C. myelin pallor (blue staining). D-E Putamen 
immunohistochemistry using antibodies specific to aSyn shows glial cytoplasmic inclusions (GCIs), 
the hallmark lesions of MSA (arrows show intra-nuclear inclusions). F. Intra-nuclear inclusions 
(arrow). 
205
. 
 
 
 
The characteristic neuropathological hallmarks of MSA are cytoplasmic inclusions in 
oligodendroglial cells called glial cytoplasmic inclusions (GCIs). aSyn is the main 
component and antibodies against it represent the most specific methods to identify GCIs; 
anyway, other proteins are found in GCIs, namely ubiquitin and p62. GCIs have variable 
diameter, 5 to 20 µm, and are located close to the nucleus. They present several 
morphologies such as triangle, half-moon, oval, conical and flame-shape, remarkably, the 
nucleus of GCIs containing cells is larger than the lacking one. Ultrastructurally, GCIs are 
randomly arranged, loosely packed filaments coated with a dense granular material 206. 
aSyn fibrils can be organized as twisted filaments (5-18 nm diameter) and straight filaments 
(10 nm diameter) 3, similarly to aSyn ones in PD and DLB. The widespread presence of 
GCIs aSyn positive classifies GCIs as unique and sufficient markers to diagnose MSA, 
even without a clinical history 207. Interestingly, aSyn can accumulate in other cell types: in 
the nuclei of oligodendrocytes to form glial nuclear inclusions (GNIs) 199, in the cytoplasm 
and nuclei of neurons as neuronal cytoplasmic inclusions (NCIs) and neuronal nuclear 
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inclusions (NNIs) 208, and in cell processes and neuritis (Fig. 6). While GNIs are difficult to 
observe, NCIs and NIIs are consistently found in MSA 209. 
GCIs present another common component: p25, also known as tubulin polymerization-
promoting protein (TPPP) 210, 211. p25 has a significant role in microtubules stabilization, 
oligodendrocytes projections, and ciliary structures212. A prominent function involved 
oligodendrocytes differentiation since p25 is expressed while the myelination process 
occurs 213, 214. Remarkably, during the neurodegeneration process, p25 delocalizes from 
myelin to the oligodendrocytes cell soma, increasing cell body size, promoting GCIs 
formation and suggesting that p25 redistribution may be an early event in the generation of 
GCIs 215. It was indeed shown that p25 presence within the cellular body favors aSyn 
aggregation, contributing to oligodendroglial dysfunction and neuronal degeneration 216. It is 
still unknown the reason why aSyn is found in oligodendrocytes since it is a protein of 
neuronal origin; furthermore studies addressing its role in non-neuronal cells have led to 
contradictory results. The analysis of aSyn mRNA levels in brain regions known to be 
affected in MSA, resulted either invariant or down-regulated in MSA brain compared to 
controls 217, 218. Differential expression of mRNA aSyn splicing variants was detected in 
MSA and PD brain 219, 220, while in situ hybridization for aSyn and proteolipid protein, an 
oligodendrocyte marker, failed to characterize aSyn expression in either MSA or control 
brains 221. Conversely, rat oligodendrocytes brain cultures expressed aSyn but in a 
developmental manner 222. Novel hypothesis are considering that aSyn expression and/or 
degradation may be up-regulated during specific steps of the neurodegenerative process or 
uptaken by neighboring neurons. The former hypothesis gained ground when detergent 
soluble aSyn was primarily found in MSA brains, while only a small amount was SDS 
insoluble, suggesting that altered solubility may precede GCIs formation 223. 
Similarly to LBs, aSyn in GCIs is found post-translationally modified: nitration 30, 224 and 
phosphorylation at Ser-129 are the major modifications 9, indicating oxidative stress and 
aSyn aggregation as principal factors involved in MSA pathogenesis. The foremost 
mechanism of pathogenesis cascade predict that early aSyn overexpression and/or 
delocalization may influence p25 distribution from the myelin to the oligodendrocytes cell 
soma, generating myelin dysfunction and increasing the cell soma size 215. This mechanism 
will initiate the neurodegeneration process, followed by microglia activation 225, aSyn fibrils 
formation and deposition in GCIs 226. This process is further enhanced by p25 delocalization 
and incorporation into the same inclusions 211. The oligodendrocytes soma gets then larger, 
the nucleus becomes pale and myelin degenerates 215. Ultimately, the formation of GCIs 
disrupts cellular functions and leads to cell death 227. Cell death may be responsible for 
aSyn aggregates release into the extracellular that may be uptaken by nearby neurons: a 
potential source for the formation of NCIs. Thus, persistent neuroinflammation 228, 
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oligodendroglial and neuronal dysfunction, and aSyn inclusions formation could altogether 
contribute to the neurodegenerative process and potentially spread it into other regions of 
the brain 229. Although there are still missing pieces in this process, this hypothesis is 
contributing to investigate the potential cellular mechanisms involved in MSA pathogenesis, 
particularly the ones that trigger aSyn presence in the GCIs. 
 
 
1.3.1. Genetics of Multiple Systems Atrophy 
 
Genetic variations can modulate susceptibility to develop sporadic forms of 
neurodegenerative diseases, recent studies have suggested that genetic factors may play a 
role also in MSA 230. Studies on few families suggested rare Mendelian inherited forms of 
MSA. In a German family with autosomal dominant inheritance, the mother and one 
daughter presented classical features of MSA whose diagnosis was confirmed 
histopathologically in the mother 231, and another family with two members affected having 
potential autosomal dominant inherited form 232. Autosomal recessive inheritance was 
described in multiple Japanese families 233, and in UK were found ten proven cases of MSA 
234. Nonetheless, these studied failed to identify a causative gene, mainly due to the limited 
number of affected individuals. 
To improve the identification of MSA related genes, screens were performed among genes 
known to be involved in other neurodegenerative diseases with overlapping pathology. 
aSyn gene, SNCA, was scanned with no positive results, although variation within the locus 
were associated with a risk of MSA 235-237. To date, SNCA is the most robust genetic 
association so far identified. 
The gene MAPT encoding for Tau protein, was also associated in pathological validated 
cases of MSA 238 and interestingly, few MSA cases present Tau localization within the GCIs 
39, 239. 
 
 
1.3.2. Animal models of Multiple Systems Atrophy 
 
Animal models of MSA are based on three different approaches: toxin-based lesion of 
striatonigral structures; overexpression of human aSyn in oligodendrocytes; and the two 
methods combined 240. 
Toxin-based models (6-OHDA, MPTP, quinolinic acid and 3-nitropropionic acid) failed to 
reproduce the characteristic pathological hallmark of MSA, GCIs, thus limiting their practice. 
20 
 
Transgenic mice model overexpressing aSyn under protein lipid promoter demonstrated 
GCIs formation and biochemical composition similar to MSA ones, although not 
argyrophilic. Mice also showed age-related loss of dopaminergic cells in the substantia 
nigra and subtle motor impairment 226, 240. Mice overexpressing aSyn under 2′, 3′-cyclic 
nucleotide 3′-phosphodiesterase (CNP) promoter presented also GCI-like inclusions in 
oligodendrocytes, degraded myelin, cortical atrophy together with age-related motor 
impairment 241. These models support evidence of neurodegeneration as a result of human 
aSyn overexpression in oligodendrocytes; nevertheless, the mild motor deficits could not 
qualify them as absolute model for MSA. 
For these reasons researchers started to use a combined approach. 3-nitropropionic acid, a 
mitochondrial inhibitor was administered to the PLP-aSyn overexpressing mice 240. This 
model showed GCI-like inclusion formations, neuronal loss in the striatum, and severe 
motor and cerebellar impairment, thus replicating many of the clinical features of MSA and 
suggesting that aSyn is the key element that renders oligodendroglial cells vulnerable to 
oxidative stress. 
Remarkably, the MSA mice models described above showed consistently microgliosis 240, 
as described in the pathological MSA cases. A recent study using aSyn overexpression 
under PLP promoter indicates that microglial activation may be an early event in the 
pathogenesis of the disease underscoring neuronal loss 242. 
 
 
1.3.3. An oligodendroglial cell model of Multiple Systems Atrophy 
 
aSyn overexpression in glioblastoma, astrocytoma cell line or rat primary mixed glial 
cultures leads to the formation of intracellular fibrils. In the same models expression of a C-
terminally truncated form of aSyn promotes further the formation of aSyn aggregates 243. In 
oligodendroglial cells derived from primary Wistar rat brain glial cultures (OLN-93 WT) aSyn 
WT and A53T mutant expression can positively model MSA, inducing aSyn aggregation, 
increasing its insolubility and promoting oxidative stress 244. This model was used in the 
study of this thesis and will receive a further description. 
In rat oligodendroglial OLN WT cells co-expression of aSyn and p25 induces aSyn-
dependent toxicity and progressive cellular degeneration dependent on the ability of p25 to 
promote aSyn aggregation 216. p25 is primarily expressed in rat nervous tissue 214 and 
localizes specifically to the cytoplasm and myelin sheaths of oligodendrocytes in adult rats 
245. p25 can play a pathogenic role in MSA since can stimulates aSyn aggregation of α-syn 
in vitro 216 and it was shown to redistribute from the myelin to oligodendrolial cell soma prior 
to accumulation and aggregation of αSyn in GCIs 215.  
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The co-expression of aSyn and p25 initiates a cellular response characterized by 
accumulation of soluble aSyn oligomers phosphorylated at Ser-129, activation of caspase-
3, retraction of the microtubules (MT) to the perinuclear region and apoptotic cell death (Fig. 
7). Apoptosis involves activation of caspase 3, phosphatidylserine externalization, nuclear 
condensation and fragmentation. The toxicity is dependent on aSyn aggregation since 
treatment with amyloid aggregation inhibitors (ASI1D peptide, baicalein and CongoRed) 
abrogates MT retraction. Most importantly, the toxicity depends on aSyn phosphorylation on 
Ser-129 because the aSyn SA mutant reduced the toxicity as well as addition of serine 
kinase inhibitors (DMAT, DRB, and emodin). Moreover, treatment with DMAT was able to 
reduce aSyn soluble oligomeric high molecular weight species 246. The same results were 
subsequently reproduced showing that oligodendroglial apoptotic cell death was partially 
rescued by sirtuin-2 inhibition 227. 
Recently, it was demonstrated that the cytotoxicity caused by co-expressing aSyn and p25 
relies on stimulation of the death domain receptor FAS and caspase-8 activation. Primary 
oligodendrocytes derived from aSyn transgenic mice express pro-apoptotic FAS receptors, 
which make them sensitive to FAS ligand-mediated apoptosis. These results were 
corroborate by an increase FAS expression found in brain extracts from MSA cases 247, 
suggesting FAS expression as an early hallmark of oligodendroglial degeneration. 
A novel study using differentiated PC12 catecholaminergic nerve cells showed that 
expression of p25 is also able to induce aSyn delocalization into autophagosomes. 
Remarkably, p25 prevented autophagosomes fusion with lysosomes, causing an increase 
in aSyn secretion to the medium. aSyn secretion was shown to be dependent on 
autophagy, suggesting p25 involvement in aSyn extracellular release and potentially its 
spread during the disease process 248. 
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Figure 7. Retraction of cellular processes in oligodendroglial glial co-expressing aSyn and 
p25. OLN WT cells transiently transfected with human aSyn and empty vector (a–c), p25 and empty 
vector (d–f), and aSyn and p25 (g–i). The retraction of microtubule (MT) processes is selective for 
the co-expression of the two proteins. 
246
. 
 
 
1.4. Alpha-synuclein 
 
1.4.1. Alpha-synuclein structure 
 
aSyn is a 140 amino acid protein present in the nervous system but also in other tissues, 
such as heart and blood. The name derived from its original localization: the nucleus and 
the pre-synaptic nerve terminals 249. It was purified for the first time as core component of 
the amyloid deposits in Alzheimer’s disease –the NAC region- subsequently identified as 
the aSyn protein 250. Thanked to the first genetic mutation identified in the aSyn gene 
(A53T) 19 and the succeeding positive staining for aSyn within LBs inclusions 1, aSyn 
became the major gene (SNCA) linked to sporadic PD. These studies demonstrated for the 
first time that aSyn is a main component of PD inclusion bodies and, mostly, the idea that 
its aggregation properties may be involved in the pathogenesis of the disease.  
The amino acid sequence of aSyn can divided into three regions: 1) the N-terminal region, 
from residue 1 to 60, characterized by six imperfect repeats of the consensus motif 
KTKEGV. This region is predicted to form amphipathic alpha-helices upon membrane and 
lipid vesicles binding 251-253. 2) A central hydrophobic region from residue 61 to 95, called 
NAC, is highly hydrophobic and crucial for fibril formation 254. 3) The C-terminal negatively 
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charged (rich in glutamate and aspartate residues) and with highly disorder structure (Fig. 
8). aSyn is highly conserved among mammals, does not exist in invertebrates, and the C-
terminal domain is the most variable in size and sequence 255. Remarkably, the majority of 
vertebrates contain the A53T disease-linked mutation, whereas in primates and human an 
alanine is present at this position 255. aSyn is a member of the synuclein family of proteins, 
which include beta and gamma-synuclein. aSyn principal difference with their family 
members is their lack of NAC domain and consequently their inability to form fibrils. All are 
mainly neuronal proteins and under physiological conditions localize preferentially to 
presynaptic terminals 256. aSyn is natively unfolded due to its high hydrophilicity and 
negative charges at the C-terminal 257, 258. Recently, this notion has been challenged by a 
study suggesting a natively tetramer conformation that result stable in aqueous solution and 
unable to aggregate 259. Notably, the majority of the studies performed until now rely upon 
the expression of a 14 kDa aSyn protein that may not mimic adequately the true native 
nature of the protein; nonetheless further analysis are essential. 
  
Figure 8. Biochemical structure of aSyn. A schematic representation of aSyn structure 
highlighting: the N-terminal region (orange), the NAC region (light blue), the C-terminal domain 
(green), the genetic mutations (bold) and the serine (red) and tyrosine (dark blue) sites of 
phosphorylation. Numbers refer to amino acid residues flanking the different regions. Ser=serine, 
Tyr=tyrosine. Adapted from 
194
. 
  
 
1.4.2. Alpha-synuclein function 
 
aSyn is an abundant protein in the nervous system, accounting for 1% of the total protein. It 
localizes mainly in proximity of pre-synaptic terminals and less prominently in the neuronal 
soma 260. It has been also found in erythrocytes and platelets, with still unknown function 
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261. Little is known about the exact physiological function of aSyn, but numerous works 
contributed to understand the role of this protein in the nervous system. aSyn expression 
levels were initially found increased during synaptic plasticity. Evidence came from studies 
on zebra finch and song learning, where aSyn homologous protein expression and pre-
syncaptic localization augmented in the brain regions involved in the bird song 262-265. 
Subsequent work exploited null aSyn animal models and/or cellular models over-expressing 
aSyn. aSyn KO mice showed altered dopamine release 160, while in primary hippocampal 
neuronal cultures treatment with aSyn antisense oligonucleotide reduced the distal pool of 
synaptic vesicles 266. Using another aSyn KO mice model, it was demonstrated that aSyn 
may be required for the maintenance of vesicles from the reserve pool and may thus 
regulate synaptic vesicle mobilization at terminals 267. Using cells over-expressing aSyn 
caused a reduction in secreted catecholamines and hypothesized that aSyn may inhibit the 
vesicle priming step prior to exocytosis 268, 269. 
Remarkably, the usage of aSyn fluorescently labeled, revealed that aSyn moved from the 
synaptic terminal during neuronal firing 270. Altogether these studies underscored a 
prominent role for aSyn in synaptic transmission. These effects are determined by aSyn 
ability to bind cellular membrane and vesicles, to interfere with phosphatidic acid 
metabolism, and to compartmentalize resting and releasable vesicles pools 266. Notably, 
aSyn can act as a chaperone to inhibit protein aggregation as for instance esterases during 
heat and pH stress 271-273. Here, the C-terminal domain is responsible for its thermal stability 
and for its chaperone activity 274. Consistently, in mice KO for cysteine string protein alpha 
(CSPalpha), which display synaptic degeneration 275, aSyn expression can alter significantly 
their phenotype. In this scenario, aSyn may chaperon CSPalpha in the assembly of SNARE 
complex 275, 276, thus controlling neurotransmitter release through the SNARE complex and 
function. 
The role of aSyn in synaptic transmission and regulation of the vesicles pool for storage or 
release of neurotransmitters may play a distinct role in the pathogenesis of PD, particularly 
modulating dopamine production and demonstrating susceptibility towards a specific 
neuronal type. Remarkably, monomeric aSyn reduces the activity of Tyrosine Hydroxylase 
(TH), the rate-limiting enzyme for the conversion of L-DOPA; this may happen at gene 
expression levels or by interacting with the enzyme 277, 278. When aSyn forms aggregates 
this modulation can be disrupted, increasing cytoplasmic dopamine. Furthermore, PD 
patients brain scan have shown decreased VMAT expression, a membrane transporter 
involved in dopamine storage 279, interestingly, this finding was not associated with aSyn 
A53T overexpression mutant, reflecting a different function from aSyn WT in dopamine 
storage 280. Similarly, aSyn can bind to the dopamine transporter (DAT) and influences 
dopamine re-uptake into the neurons 281, 282. 
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1.4.3. Alpha-synuclein aggregation  
 
aSyn is a highly dynamic protein characterized by intermediate states of fibrillization. In vitro 
studies demonstrated that aSyn generates under prolonged time of incubation, fibril-like 
structures considered similar to LBs inclusions 283, 284. Initially, aSyn forms oligomeric 
soluble species with spherical, ring, and string-like appearances as shown by electron 
microscopy 285-287. Oligomeric soluble species are difficult to detect in vivo, but, recent 
studies using native gels or size-exclusion chromatography have managed to characterize 
them 288-290. Oligomeric species gradually generate structures named protofibrils and, 
ultimately, recruiting more monomer, they aggregate into insoluble fibrils (Fig. 9) 291 . This 
so-called nucleation-dependent mechanism is divided in a lag phase: oligomers structure 
will form; and a rapid growth phase: fibril formation via monomer addition; for then reaching 
a steady-state where equilibrium between monomeric and fibrillar species is formed 292 (Fig. 
9). 
aSyn fibrils represent the pathological state of the protein since it was demonstrated a lack 
of aSyn toxicity without the NAC aggregation-promoting domain 254, 293, 294, and a protection 
mechanism by overexpressing HSPs (chaperones that assist other proteins into their 
correct re-folding) 295-297. Conversely, oligomeric species are considered the toxic ones. A 
severe dopaminergic loss was shown only in rats treated with aSyn mutants that form 
oligomers (E57K and E35K), while those that formed fibrils were less toxic 290. Dopamine 
and its metabolites can also inhibit formation of mature fibrils both in vitro and in vivo 298, 
suggesting that dopaminergic vulnerability in PD may be linked to increase aSyn oligomers 
formation. Furthermore, oligomers were also found in plasma and cerebro-spinal fluid of PD 
patients and their levels seem to correlate with the disease state 299, 300. Oligomeric species 
of aSyn WT and A53T mutant have been described in brain tissue from aSyn transgenic 
mice and PD patients 301, and elevated levels of soluble oligomers have also been detected 
in post-mortem brain extracts from DLB patients compared to control brains 302. 
It is necessary to mention that some protofibrils are not toxic, the so-called “off-pathways”, 
while formation of larger aggregates can also engulf and disrupt the intracellular neuronal 
machinery, therefore the toxicity induced by oligomeric aSyn is still under debate. 
Conditions influencing aSyn aggregation can be: non-specific molecular crowding 303 and 
protein concentration 304. These reflect possible pathological mechanisms: multiplication of 
aSyn gene is known to promote oligomeric formation and mitochondria dysfunction 44, 305, 
and aSyn oligomers and larger aggregates seem able to block proteasome degradation 79, 
80, 306. Remarkably, aSyn mutants can promote aSyn oligomerization, but only A53T mutant 
can augment aSyn rate of fibrillization 283, 285, 307-309. Further studies demonstrated that 
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membrane-bound aSyn has higher propensity to aggregate 310, similarly, induced oxidative 
stress (treatment with peroxynitrite and rotenone) can also enhance aSyn aggregation 311-
313 and cell toxicity in rats model of PD 147, 314. aSyn is able to bind metal ions modulating its 
oligomerization state, for instance copper-induced oligomeric specie can be cytotoxic 286, 
while Fe3+-induced oligomers can form permeating pores at lipid-bilayers 315.  
 
 
Figure 9. Nucleation of aSyn aggregates. aSyn monomers can form soluble dimers/oligomers that 
successively can accumulate into insoluble species (filaments, protofibrills, fibrils and aggregates). In 
this scenario oligomeric species seem to be more toxic than larger protein aggregates. aSyn 
aggregation propensity can arise from increased gene dosage, environmental factors or non-specific 
moleculr crowding. Adapted from 
185
. 
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1.5. Alpha-synuclein post-translational modifications 
 
Several PTMs are known to occur in aSyn present in the LBs of PD patients and related 
diseases. Also, several of them have been identified in animal models of synucleinopthies. 
However, it is not clear yet, how these PTM affect aSyn structure and folding behavior and how 
they modulated the pathogenesis of the disease. Here, we will summarize the principal 
modifications associated with the disease and the current knowledge on their role on aSyn 
pathobiology.  
 
1.5.1.  Alpha-synuclein phosphorylation 
Phosphorylation is the most common post-translational modification used to modulate or 
change a protein function. aSyn is physiological phosphorylated on Ser-129 and Ser-87 
residues in cell cultures 316. The discovery that aSyn was also phosphorylated on Ser-129 in 
synucleinopathies lesions propelled studies on the role of this PTM in aSyn function and 
misfolding behavior 9. Immunohistochemistry analysis of synucleinopathies brain tissues 
found out that 90% of aSyn deposited in LBs was phosphorylated at Ser-129, compared 
with the physiological 4% of normal brains 317, 318. For the first time, the role of aSyn 
phosphorylation on Ser-129 became prominent and, remarkably, a shared phenomenon in 
the spectrum of synucleinopathies. Notably, phosphorylation of aSyn at Ser-129 increases 
during LBs formation, that is, when aSyn was turning into an insoluble protein 319. The same 
study identified truncated and ubiquitinated forms of aSyn in LBs, but at much smaller 
proportion compared with phosphorylated ones 319. aSyn can indeed undergo several PTMs 
while deposited in the LBs; it can be phosphorylated at serine and tyrosine residues, 
truncated, nitrated, ubiquitinated, sumoylated, acetylated and enzymatically crossed-linked 
(Fig. 11).  
Remarkably, aSyn phosphorylation was reproduced and correlated with PD pathology in 
numerous animal models: in transgenic mice over-expressing aSyn 226, 320-322, in aSyn 
transgenic rats 323 and flies 324, 325. 
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Figure 10. aSyn potential phosphorylation sites and associated kinases in humans. (S=serine, 
Y=tyrosine, T=threonine). Adapted from 
326
. 
 
 
1.5.1.1. Phosphorylation at Serine residues 
aSyn contains four serine residues: serine 9 and serine 42 (N-terminal domain); serine 
87 (NAC region) and serine 129 (C-terminal domain); whith serine 129 residue highly 
conserved among species (Fig. 9). Serine 87 and serine 129 were characterized using 
phosphorylation mutants (aSynSA that mimics the non-phosphorylated state of the 
protein) in cell lines 316; serine 129 (Ser-129) phosphorylation was identified in LBs 9; 
while only in 2010 phosphorylation of aSyn at serine 87 (Ser-87) in LBs was discovered 
327.  
The natural kinases and phosphatases involved in aSyn serine 
phosphorylation/dephosphorylation remain unknown, but potential candidates have 
been identified in vitro and in vivo. Kinase specific for Ser-129 are G coupled-receptor 
kinase 1, 2, 5 and 6 (GRK) 328, 329 and the Polo-like kinases 2 and 3 (PLK) 330, 331. Casein 
kinase 1 and 2 (CK) can phosphorylate aSyn both at Ser-87 and Ser-129 residues 316. 
CK2 and GRK-5 were also found in LBs 332, 333 (Fig. 9). Not all the kinases have the 
same efficiency to phosphorylate aSyn; remarkably PLK2 and PLK3 can fully 
phosphorylate aSyn in vitro 330, 331 both in monomeric and fibrillar states 331, 334; while in 
cerebral cortex of PLK2 KO mice phosphorylated aSyn was significant reduced 330. 
PLK2 cellular levels seem regulated by the ubiquitin–proteasome system 335 since 
during synaptic stimulation proteasome inhibition leads to an increase in PLK2 levels 
336. Interestingly, PLK2 expression levels were found elevated in post-mortem brain 
tissue from subjects with AD and LBD 331. Amongst phosphatases, in vivo studies 
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showed that Phosphoprotein Phosphatase 2A can dephosphorylate aSyn on Ser-129 
337, while in vitro studies characterized Phosphoprotein Phosphatase 2C 338. 
The effect of phosphorylation on aSyn toxicity and aggregation remains still 
controversial; the choice of different model system and/or methodological approaches 
produced many discrepancies. In a transgenic Drosophila model, expression of 
aSynSD phosphorylation mutant (mimics the phosphorylated state of the protein) 
induced dopaminergic loss that was totally reverted when the aSynSA mutant was 
instead expressed. In the same model co-expression of aSyn WT and GRK2 increased 
aSyn Ser-129 phosphorylation levels and cell toxicity 325. In the first recombinant adeno-
associated virus (rAAV) based rat models of PD, 339 expression of S129A generate loss 
of substantia nigra dopaminergic neurons, whereas S129D reverted it. In a subsequent 
rat model, S129A was shown to increase dopaminergic cell loss, while S129D did not 
alter it 340, while in a third model it was reported no difference in dopaminergic neuronal 
cells expressing either aSyn WT, S129A, or S129D 341.  
As alternative, in vivo mediated aSyn phosphorylation co-expressing in rats GRK6 
kinase with aSyn genetic mutant A53T enhanced toxicity, while the S129A mutant did 
not display any changes compared with aSyn WT 342. Similarly, a transgenic mouse 
model over-expressing aSyn with an enhanced PP2A phosphatase activity, showed a 
better motor performance and increased neuronal activity, but data on dopaminergic 
cell loss were not assessed 337. These studied clearly exemplified the complex nature 
behind aSyn phosphorylation on Ser-129 and the difficulties to model such a peculiar 
PTM in animal models of PD. On top of this, methodological approaches may affect the 
results and render them difficult to compare. For instance, aSyn expression levels, the 
viruses serotype, and observational time points resulted different in the various models 
343; furthermore it was demonstrated that the phospho-mimicking mutant S129D does 
not replicate the structural properties of authentically Ser129-phosphorylated aSyn. 
Therefore, the results obtained with this mutant have to be considered critically 344. 
The role of aSyn Ser-129 phosphorylation on aSyn aggregation is also under intense 
debate. In vitro data reported opposite results: Ser129 phosphorylated may or may not 
inhibit aSyn fibrillization 9, 344. In a transgenic fly model, Ser-129 phosphorylation 
suppressed formation of aSyn aggregates 325 and reduction in aSyn C-terminal charge 
seems to favor formation of fibrillar species 345. Further data suggested that Ser-129 
phosphorylation may occur after aSyn aggregation 331, 334. Recently, it was described 
that formation of aSyn insoluble species parallel an increase in soluble and lipid-
associated aSyn Ser-129 phosphorylated in PD and DLB brain tissues in regions still 
not presenting LBs, suggesting that Ser-129 phosphorylation may occur before aSyn 
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aggregation 346. In addition other data showed that induction of phosphatase 2A can 
reduce aSyn aggregation 337.  
Others authors focused on the physiological role of aSyn phosphorylation to try to 
narrow which process may be principally involved in PD pathogenesis. Studies 
demonstrated that Ser-129 phosphorylation can be a signal for aSyn nuclear 
localization 321, 331, 347. Nuclear staining was indeed confirmed in numerous model 
systems: in transgenic mice for A30P and A53T aSyn mutants compared with control 
ones 348; in HEK cell line over-expressing aSyn and GRK5 compared with WT one 331, 
347. The consequences of this localization are unknown but studies revealed that aSyn 
may play a function in transcriptional regulation since nuclear translocation was shown 
in response to the herbicide paraquat 349, and to reduce histone acetylation 350. 
Moreover, inhibitors of histone deacetylase (HDAC) rescued aSyn mediated toxicity in 
cell cultures and in Drosophila models 350.  
Phosphorylation can be also a signal for protein degradation as proteasome inhibition in 
cell and primary neurons increased aSyn phosphorylation on Ser-129 351, 352. This 
phenomenon was shown to be ubiquitin independent 352.  
aSyn can bind to numerous proteins such as TH and the dopamine transporter (DAT), 
modulating their function 277, 353-355.  Remarkably, some interactions can modulate its 
aggregation propensity: synphilin-1, a protein identified through a yeast two-hybrid 
screen as aSyn interacting protein, can promote aSyn aggregation and inclusion 
formation 13. In yeast co-expression of aSyn and synphilin-1 accelerated inclusion 
formation, and, interestingly co-expression of synphilin-1 mutant R621C (a genetic 
association found in idiopathic PD cases, 356) enhaced also aSyn phosphorylation at 
Ser-129. Furthermore, synphilin-1 inclusions co-localized with lipid droplets and 
endomembranes 357.  
Furthermore, aSyn interaction can sequestre arachidonic acid within the SNARE 
complex inhibiting neuronal transmission 358, and impair the hydrolysis of 
phosphatidylcholine to phosphatidic acid regulated by the enzyme phospholipase D 
(PLD) 359, 360. Although this latter finding was not always consistent 361, PLD is linked to 
neurotransmitter release 360 therefore lipids balance may be required for proper synaptic 
function and alteration of this mechanism may play a role in aSyn toxicity. Similarly, 
polyunsaturated fatty acids (PUFAs) have been shown to enhance aSyn 
oligomerization and toxicity 301, 362, 363.  
To date, only phosphorylation at Ser-129 and Ser-87 has been linked to PD. Ser-87 is 
not conserved amongst species, for instance mice and rats have an asparagine in 
position 87 and aSyn is found phosphorylated at Ser-87 in LBs and its levels were 
increased in AD, MSA and PD brains 327. Phosphorylation at Ser-87 is preferentially 
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found in membrane fractions and kinases CK1/2 316 and the dual specificity tyrosine-
regulated kinase Dyrk1A were associated with it 364. Ser-87 lies within aSyn NAC region 
and can modulate aSyn fibrils formation; in vitro studies demonstrated that Ser-87 
phosphorylation or using phosphorylation mutants (S87D/E) inhibits aSyn fibrillization 
327, 365. In vivo findings corroborate this function in parallel with a protective mechanism 
toward dopaminergic cell loss 366. 
 
 
 
1.5.1.2. Phosphorylation at Tyrosine residues 
Tyrosine phosphorylation is known as a very rapid process, difficult to analyze in vivo 
and that happens rarely in proteins. aSyn contains four conserved tyrosine residues: 
Tyr-125, Tyr-133 and Tyr-136 in the C-terminal domain and Tyr-39 in the N-terminal 
domain (Fig. 7). aSyn was initially shown to be phosphorylated on Tyr-125 in cell 
culture only upon treatment with pervanadate, a non-specific phosphatase inhibitor 367. 
Subsequent in vitro kinase assays confirmed Tyr-125 as main phosphorylated tyrosine 
residue in aSyn 368-370. Remarkably, in a Drosophila model aSyn resulted 
phosphorylated on Tyr-125, a signal enhanced upon inhibition of phosphatases 371.  In 
vitro and cell culture studies demonstrated that Tyr-125 phosphorylation is mediated by 
several tyrosine kinases namely Fyn 367, 368, Pyk2/RAFTK 369, c-Src 367, 369, and c-Fgr 370; 
and at the three tyrosine residues Tyr-125, Tyr-133 and Tyr-136 by Syk 370 (Fig. 10). 
The physiological phosphatases involved in aSyn tyrosine dephosphorylation remain 
unknown. 
Initial studies did not reveal any association between Tyr-125 phosphorylation and aSyn 
pathobiology 367, 368; however shortly after it was reported that aSyn phosphorylation at 
Tyr-125 was induced by hyperosmotic stress 369 or by rotenone treatment 372. 
Remarkably, in the only study from human brain tissue patients, the levels of Tyr-125 
phosphorylation were shown to decrease with age and with PD pathology, suggesting 
its association with the disease 371.  
Single tyrosine residue analysis has not been properly investigated yet, but 
phosphorylation of Tyr-125, Tyr-133 and Tyr 136 was shown to inhibit aSyn 
oligomerization and inclusion formation 370. Similar conditions were addressed in flies 
expressing Shark kinase, a homolog of Syk, and the same effect on aSyn 
oligomerization was observed 371. Furthermore, the same study characterized the effect 
of triple tyrosine phosphorylation mutants to mimic the non-phosphorylated state of the 
protein (Y125F/Y133F/Y136F). These flies showed loss of dopaminergic neurons and 
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reduction in climbing activity compared with control ones. These findings suggest a 
protective mechanism for aSyn tyrosine phosphorylation.  
Other potential roles for Tyr-125 phosphorylation may be dependent on protein-protein 
interactions: the phospho tyrosine 125 peptide was shown to interact more 
preferentially with CK1 than the phospho serine 129 peptide 373 this may indicate a 
potential cross-talk between the two phosphorylation sites. Phosphorylation at Tyr-125 
is also able to increase aSyn binding to bivalent cations such as Cu2+, Pb2+ and Fe2+, 
although similar findings were also observed for Ser-129 phosphorylation 374. 
 
Figure 11. Major aSyn post-translational modifications found in Lewy Bodies. 
These include phosphorylation, ubiquitination, truncation, nitration and covalent cross-
linking by tissue transglutaminase 326.  
 
 
1.5.2. Alpha-synuclein ubiquitination 
In 1998, ubiquitin was found to co-localize with aSyn in LBs. Subsequent biochemical 
analysis of PD brain insoluble fractions demonstrated that not only ubiquitin was present in 
the LBs but that aSyn itself was ubiquitinated 375. aSyn can be mono- di- and to a less 
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extent poli-ubiquitinated at Lys-12, Lys-21 and Lys-23 as mass spectrometry studies 
revealed 375-377 and in vitro and cell culture studies confirmed 319, 378, 379. Interestingly, some 
ubiquitinated forms were also phosphorylated at Ser-129 375. Several E3 ligases have been 
reported to ubiquitinate aSyn: seven in absentia homologue-1 (SIAH-1) mono-ubiquitinqted 
aSyn at Lysine residues 12, 21, 23 (as within LBs) but also at Lysines 10, 34, 43, and 96 
380; Nedd4 poly-ubiquitinated aSyn through Lys-63 ubiquitin chains 381; TRAF6 and CHIP 
can also ubiquitinate aSyn 87, 382.  
Not all aSyn inclusions in PD patients are ubiquitin positive, suggesting that ubiquitination 
may not be required for aSyn aggregation 376. Initial studies showed that aSyn ubiquitination 
promotes its aggregation, and cells over-expressing E3 ligase SIAH-1 presented an 
increase in aSyn aggregation 378. Similarly, in vitro ubiquitination also increases aSyn 
fibrillization 380.  
Protein ubiquitination is used to target proteins for degradation, in the case of aSyn studies 
showed dissimilar scenarios. Pharmacologically impairment of proteasome did not lead to 
aSyn ubiquitination 377, 383, while others described the opposite 384; or showed that aSyn can 
be degraded via proteasome without ubiquitin signal 352, 385, 386. Co-expression of aSyn and 
SIAH-1 did promote its degradation in presence of proteasome inhibitors 378; however, aSyn 
incubation with SIAH-2 in presence of the proteasome subunit 26S was sufficient to 
promote its degradation 379. Recently, it was demonstrated that Nedd4 aSyn mediated 
ubiquitination favors its degradation via the lysosomal-endosomal pathway 381. These data 
suggest that ubiquitination may play a role in aSyn degradation, but the mechanism may 
depend on ubiquitination sites and/or enzymes involved. 
 
1.5.3. Alpha-synuclein truncation 
Proteomic analysis of LBs revealed also the presence of aSyn truncated forms, recognizing 
several aSyn proteolytic products: 1-134, 1-133, 1-126, 1-122, 1-119, 1-115 and 1-96 319, 
387, 388. The same species were also identified in transgenic mice models of PD 155, 156, 388; 
however, aSyn truncated species exist also in healthy brains. In vitro analysis 
demonstrated that aSyn truncation can promote its aggregation and can be considered an 
important factor into aSyn misfolding behavior 389-391. In vitro assays, indeed, have so far 
constantly showed that aSyn C-terminal truncation promotes fibril formation and can seed 
aggregation of the full length protein 388. In cell culture studies, overexpression of the 
truncated forms, 1-110 and 1-120, increased vulnerability to oxidative stress compared to 
the full-length protein 388. Drosophila models expressing the truncated 1-87 form showed 
increased aSyn accumulation and enhanced neurotoxicity 294, however the over-expression 
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of aSyn truncated forms in rodent models did not so far reproduce PD pathological 
conditions 319. To date, several proteases were found responsible for aSyn truncation: 
neurosin generates primary 1-80 residues fragments 392, 393, calpain I cleaves aSyn within 
the NAC region and aSyn fibrils after residue 120 394, 395, and cathepsin D cleaves aSyn C-
terminally 396; also the 20S proteasome subunit can cleave aSyn, but only in monomeric 
free form 388. 
 
1.5.4. Alpha-synuclein oxidation 
ROS and nitrogen species can generate 3-nitrotyrosine aSyn, a modification identified in 
LBs 30. All four aSyn tyrosine residues (Fig. 7) are found nitrated in LBs of PD brain patients 
30; oxidative stress can mediate aSyn covalent cross-linking via di-tyrosine formation; a 
mechanism that can stabilize aSyn oligomers in vitro, inhibiting aSyn fibrils formation 397, 
and can contribute in vivo to the formation of oligomeric species 398. In rats model nitrated 
aSyn was shown to be toxic to dopaminergic neurons leading to motor deficit, most 
probably due to the action of aSyn oligomeric species 314. 
All four aSyn methionine residues can be oxided in vitro to methionine sulfoxide. This 
modification can disrupt aSyn structure, blocking its propensity to form both oligomers and 
fibrils 399. It was shown that the inhibition of aSyn fibrils formation is proportional to the 
number of methionine residue oxided 400. Conversely, methionine sulfoxides can bind to 
metal ions such as Zn2+, Pb2+ and Al3+ and promote aSyn fibrillization 401. 
Dopamine itself can be higly oxidized, a status that binds aSyn inducing the formation of 
SDS insoluble aSyn oligomers formation 402. 
 
1.5.5. Alpha-synuclein acetylation  
aSyn is also ubiquitously acetylated at its N-terminal metionine residues in LBs 319. This 
PTM seem unable to affect aSyn aggregation propensity or subcellular localization 403-406, 
although inhibition of sirtuin 2, a mammalian HDAC that increases acetylation, was 
associated with neuroprotection in various models of synucleinopathy 407, 408. 
 
 
1.5.6. Alpha-synuclein sumoylation 
Recently aSyn was shown to be sumoylated at Lys-96 and Lys-102. The protein 
responsible for this PTM are SUMO1, and to a less extent SUMO2 409. Small-ubiquitin-like 
modifiers (SUMO) are proteins that possess structural similarities to ubiquitin. Although the 
35 
 
significance of aSyn sumoylation has to be explored, recent studies have suggested that 
aSyn sumoylation may prevent its aggregation and that even small amounts of sumoylated 
proteins can inhibit aSyn aggregation 410. 
 
 
1.5.7.  Alpha-synuclein transglutaminase cross-linking 
 
aSyn is highly cross-linked between lysine and glutamine residues in dopaminergic neurons 
of PD and the extent correlated with the disease progression 411. Glutamine 79, 99 and 109 
were found as residues acceptors for Lysine 60 residue donor at the N-terminal of aSyn 412. 
Cross-linking inhibited aSyn fibrils formation and promoted oligomer unstructured formation 
413 that are unable to disrupt lipid bilayers. However, the effect of cross-linking on aSyn was 
shown to be dependent on the position of the cross-link; with the majority generating aSyn 
non-toxic oligomers. 
 
 
 
1.6. S. cerevisiae as a model for neurodegenerative diseases 
 
Many of the significative advances in our understanding of the pathogenic mechanisms 
underlying PD have exploited yeast as model system; the usefulness of this organism in 
respect of higher eukaryotes resides in the conserved homology of genes and pathways in 
such distant evolutionary context. This knowledge was fundamental to discriminate which 
pathways were involved in diseases context and permitted a powerful approach to the field of 
neurodegenerative research.  
Saccharomyces cerevisiae was the first eukaryote to be completely sequenced in 1996 414. 
6,600 open reading frames (ORFs) (genome sequence that encode proteins) are characterized 
and 80% functionally described 415, 416. Remarkably, 60% of the yeast genes present a human 
homologous or a domain that is functionally correlated with a human one 417. Homology to 
yeast genes has often applied to identify novel genes in higher eukaryotes, and among the 
several biological processed involved in the neurodegenerative diseases, the majority result 
conserved in yeast, such as transcriptional factors, protein targeting and secretion, cytoskeletal 
dynamics and protein quality control. Together with its genetic manipulability and short 
generation time 418, these features rendered yeast the ideal model for high-throughput 
screening 419. Yeast phenotypes resulting from genetic, environmental or chemical causes can 
be analyzed by genome-wide screens, transcriptional profiling, proteomic and lipidomic 
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analysis. A collaborative yeast scientific community guarantees that the data produced can be 
screened against public available databases such as genome-wide deletion, reduced 
expression or overexpression libraries 420. Such libraries include collections of plasmids for 
manipulating the expression of every ORF of the yeast genome – as the one used in our study. 
Yeast does have limitations such the lack of interplay between immune and inflammatory 
responses, and of a nervous system; furthermore mammalian cells have several cellular 
specializations without homology in yeast. Despite critics, yeast has been an utterly informative 
system to identify novel genes and environmental connection in neurodegenerative disorders, 
and to identify new therapeutic targets 421. 
The basic pathways altered in neurodegenerative diseases are highly conserved between 
yeast and human species; therefore, the fundamental molecular events involved in these 
disorders can be studied in yeast 73. Protein quality control was the first process analyzed in 
yeast and involved in neurodegenerative diseases. Protein misfolding that result into 
generation of proteinceous inclusions is one of the key pathological hallmarks of these 
disorders. The first recognized misfolding disease is caused by prions: infectious protein 
particles transmissible from cell to cell, in a non-Mendelian inheritance 422. Although no 
homology was identified with yeast prions, the biochemical analysis performed in this model 
identified the protein mechanism of infection. Yeast allowed the concept of one-protein as 
pathogenic element and the idea that a misfolded protein could serve as a template for healthy 
ones in order to propagate the infection 422, 423.  Moreover, yeast studies demonstrated the 
molecular mechanisms used by prions to generate different strains, and the mechanism used 
to overcome species barriers 424, 425.  
Mitochondrial dysfunction is another central feature of neurodegeneration. The ability of yeast 
to ferment helped to identify novel genes involved in the mitochondria function, in condition 
that can be lethal for other mammalian organism. Yeast permitted also to identify genetic 
suppressors of ROS aSyn fibrils-mediated production that had failed in presence of  A30P or 
A53T aSyn mutants; suggesting that WT aSyn toxicity mechanisms differ from those of the two 
familial mutants forms 426. 
The finding that key conserved genes within the vesicle mediated transport between the 
endoplasmic reticulum (ER) and Golgi were conserved between yeast and humans and, most 
importantly, involved in aSyn pathobiology represented a milestone discovery 71. Furthermore, 
co-expression of aSyn and Rab1, the mammalian ortholog of the yeast Ypt1 protein (known 
yeast gene suppressor of aSyn toxicity), was shown to suppress the loss dopaminergic 
neurons 71, 73. Subsequently, other studies identified defects in the vesicular trafficking 
machinery related with aSyn pathology 427-429. Yeast deletion mutants were also used to 
identify genes involved in endocytosis and vacuolar degradation 407. 
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Finally, yeast present conserved mechanism of cell death and survival, where apoptosis-like 
process was initially inferred by the similar morphology of dying yeast with mammalian cells. 
These similarities involved: DNA fragmentation, chromatin condensation, release of 
cytochrome c, and exposure of phosphatidylserine at the plasma membrane 430. Furthermore, 
several apoptotic mammalian regulators present orthologs in the yeast genome; such as 
apoptosis inducing factor (AIF) and superoxide dismutase (SOD). Although yeast missed one 
of the key elements of programmed cell death, Bcl2, when the human protein is co-expressed 
in yeast can protect from mitochondrial cell death. This mechanism demonstrates that 
heterologous expression of a human protein, Bcl2, absent in yeast, can maintain conserved 
protein interactions and function in an evolutionary context 431, 432.  
Recently, autophagy has become a potential cell death mechanism involved in 
neurodegeneration. Once again, yeast was used to shed light into possible gene target. The 
autophagy machinery consists on the highly conserved Atg proteins family, downstream of the 
target of rapamycin (TOR) kinase. Deletion of Atg proteins in mammalian neurons produced 
accumulation of misfolded proteins, and genetic and pharmacologic inhibition of TOR resulted 
neuroprotective 433. 
However versatile the yeast model can be, the biological differences between yeast and 
complex human diseases require validating the insights gained from yeast in mammalian cell 
models. 
 
  
 
Figure 12. Effects of aSyn expression in yeast cells. On the top panel, fluorescence microscopy 
of yeast cells expressing aSyn-GFP. In cells carrying one copy of aSyn, the protein localizes mainly 
at the plasma membrane. Cells with two copies show instead cytoplasmic inclusions (foci), while 
aSyn cloned into a 2 μ plasmid distributes variably within cells; some presenting foci others 
membrane-bound pattern. On the bottom panel, growth in solid media of one copy of aSyn (b) has a 
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minor effect, whereas two copies (c) completely inhibit it. aSyn 2 μ plasmid expression causes mild  
inhibition of cell growth (d)
434
. 
 
1.6.1.  S.cereviasiae as a model for Parkinson’s disease 
 
Two main strategies can be used to model neurodegenerative diseases in yeast 419. If the 
gene involved has a known homologous in yeast, it can be over-expressed or deleted and 
the subsequent phenotype analyzed. For instance, the autosomal-recessive 
neurodegenerative disorder Friedreich’s ataxia is caused by a reduction of a protein called 
frataxin, encoded by FRDA gene. The yeast FRDA homologue YFH1 has been crucial in 
determining its function 435. If the gene involved does not have yeast homologous, the 
human one is over-expressed in yeast and screened for a phenotype. This situation would 
particularly match autosomal dominant diseases where the gene product accumulation is 
one of the major features of the disease, thus the over-expression in yeast can reproduce 
the main pathological hallmark of the disorder. Classic examples are: Huntington’s disease 
and polyglutamine disorders, Parkinson’s disease and synucleinopathies, and Alzheimer’s 
disease 421. 
For the purpose of this thesis we will only described the yeast model of PD. aSyn inclusion 
formation known as LBs are the primary hallmark of a group of disorders called 
synucleinopathies, including PD. The first yeast model of PD was based on the 
heterologous expression of different variants of human aSyn. aSyn is conjugated to a green 
fluorescent protein (GFP), present a galactose inducible promoter and it is cloned within 
vectors that allow different expression levels. The presence of GFP does not alter the 
biology of the protein in yeast, thus providing a powerful tool to study aSyn subcellular 
localization. In this model, at increasing level of expression, aSyn-GFP moves from the 
plasma membrane to intracytoplasmic inclusions (Fig. 12) 434. Just doubling aSyn 
expression levels can lead to the accumulation of aSyn in cytoplasmic inclusions, referred 
as foci, growth inhibition an ultimately cell death 434. In addition to aSyn aggregation, using 
this model, crucial events of PD pathology were also reproduced, namely: defective vesicle 
trafficking 71, 73, 436, ROS production 437, 438, mitochondrial dysfunction 439, proteasome 
impairment 434, 437, 440 and lipid-droplet accumulation 407, 441.  Since then, numerous studies 
were performed using yeast to model different aspects of PD 442-445 and novel mechanism 
unravelled as autophagy/mitophagy dysfunction 446, 447. 
The first yeast genetic screening used a collection of deleted non-essential genes to identify 
enhancers of aSyn toxicity 448; the same collection was used to identify modulators of aSyn 
aggregation and cellular localization, remarkably similar pathways were identified: lipid 
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metabolism, vesicular transport, and vacuolar degradation 407. Subsequent microarray 
analysis at different times point post aSyn expression induction validate these findings, 
underscoring defects as mitochondrial dysfunction, ER stress, vesicle trafficking and sterol 
biosynthesis 449. Screens of small molecules for therapeutic purposes identified two cyclic 
peptides and four 1,2,3,4-tetrahydroquinolinones as suppressors of aSyn toxicity 449-451. 
Other PD related genes have been studied in yeast: for instance, yeast 2-hybrid analysis 
identified interactors of LRRK2 452, 453 and another study associated LRRK2 toxicity with 
defects in endocytic vesicular trafficking and autophagy, observation then validated in 
primary neuronal models 454. Yeast models contributed to the functional analysis of the 
human lysosomal ATPase ATP13A2 455-458. The yeast ortholog, YPK9, a vacuolar 
membrane transporter is a known suppressor of aSyn toxicity 455; notably, PD associated 
mutations delocalize Ypk9p, supporting a loss-of-function mechanism 455. 
To date, aSyn related toxicity involve several cellular pathways that were initially described 
in yeast and then corroborate in other animal PD models or successfully recapitulated in 
yeast. 
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2. Aims of the study 
 
In this study, we analized the role of aSyn phosphorylation on Ser-129 by Polo-like kinases 
(PLKs) in established yeast and mammalian cell model of PD, and we addressed the role of 
tyrosine phosphorylation in an oligodendroglial cell model (OLN) of MSA. The major aim of this 
project is to understand the potential role of aSyn phosphorylation in terms of cytotoxicity, and 
oligomerization/aggregation. To this purpose several approaches were used:  
1. We co-expressed human kinases previously known to phosphorylate aSyn, namely PLKs, 
together with aSyn and we assessed aSyn phosphorylation levels on Ser-129, the effect on 
cell viability and aSyn aggregation. We proceed to validate the results obtained in yeast in 
mammalian cell models of PD. We co-expressed aSyn and synphilin-1 in cathecolaminergic 
cell line (CAD) together with the four members of PLKs and we assessed the level of aSyn 
phosphorylation at Ser-129 and its aggregation state. We then used the same approach in 
neuroglioma cell line (H4) in order to determine the effect of aSyn Ser-129 phosphorylation 
on aSyn oligomerization. In this case we used a bimolecular fluorescence complementation 
(BiFC) assay that enables the direct visualization of protein interactions in their typical 
subcellular environment.  
2. We performed a functional screening in yeast to identify novel kinases involved in aSyn 
pathobiology. We identified kinases homologous with human ones and co-expressed with 
human aSyn. We then assessed the effect on aSyn intracellular toxicity, foci formation and 
phosphorylation levels on Ser-129. 
3. We analysed the role of aSyn tyrosine phosphorylation on aSyn cytotoxicity and cellular 
degeneration in an oligodendroglial cell model (OLN) of MSA (this subproject is carried out 
as a Neurasync lab secondment in the laboratory of Prof. Poul Henning Jensen, Aarhus 
University). We co-expressed in oligodendroglia cell line aSyn WT and p25, a tubulin 
promoting polymerizing protein. The co-expression of p25 and aSyn induces aSyn 
aggregate dependent toxicity characterized by retraction of the microtubule (MT) 
cytoskeleton and dependent on Ser-129 phoshorylation. We explored the role of aSyn 
S129A/Y/F and aSyn Y/F tyrosine phosphorylation mutants (mimics tyrosine non-
phosphorylated state) on aSyn toxicity and microtubule retraction. 
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3. Materials and Methods 
 
Cloning of PLKs, aSyn, and synphilin-1 
The yeast expression vectors p426GAL was used to express human aSyn under a galactose-
inducible promoter and fused with GFP, as described before 434. Briefly aSyn was cloned into 
p426GPD as SpeI-HindIII digested product of PCR amplification. GFP fusion was constructed 
the correspoding coding sequence as a ClaI-XhoI digested PCR product in frame with aSyn. 
aSyn fused with GFP was subcloned into p426GAL, p423GAL as SacI-KpnI fragment. 
Constructs were verified by DNA sequencing. 
The PLKs mammalian expression plasmid pCMV6 was a kind gift from Dr. Hilal Lashuel, Ecole 
Polytechnique Federale de Lausanne, Switzerland. For the PLKs expression in yeast cells, the 
PLK1 Myc-FLAG gene was excised from pCMV6 and cloned into the ClaI and EcoRI sites of 
pRS423GAL, while PLK2 Myc-FLAG, PLK3 Myc-FLAG and PLK4 Myc-FLAG genes were 
excised from pCMV6 and cloned into the ClaI and BamHI sites of p423GAL. The p423GAL 
PLK2 K111M mutant was generated by site-directed mutagenesis using primers: 5’ primer: 
CAAAGTCTACGCCGCAATGATTATTCCTCACAGCAG and 3’ primer: 
CTGCTGTGAGGAATAATCATTGCGGCGTAGACTTTG (Stratagene: QuikChangeTM Site-
Directed Mutagenesis Kit). SynT plasmid (aSynEGFP deletion mutant (WTSynEGFP∆155)) 
was previously described 183; briefly it was generated using PCR with an antisense primer 
directed to sequences within GFP to remove 465 bp from the C-terminal. aSyn cDNA  was then 
amplified by PCR and cloned into pSI (Promega, Madison, WI, USA) vector. The truncated 
aSyn-GFP fusion protein has only 93 amino acids of GFP fused to its C-terminal. This fusion 
protein is no longer fluorescent but has a propensity to aggregate; co-transfection with 
synphilin-1 further enhances this propensity, thus co-transfection of Syn-T plus synphilin-1 
functions as aSyn aggregation model. Synphilin-1 plasmid was also previously described 13, 357. 
 
Cloning of aSynS129A, aSynYF and aSynS129AYF 
The oligodendrocytes expression plasmids used were made by Jennifer Skaarup Koffman 
(former Master student at Dr. Poul Henning Jensen laboratory, Biomedicine Department, 
Aarhus University).  The coding sequences of human aSyn WT and p25 were inserted into 
XbaI and NotI restriction sites of the pcDNA3.1/zeo(-) vector (Invitrogen). S129A mutation was 
generated by single nucleotide substitution of TCT to GCT using forward primer 5’-
ATAATAGCTAGCATGGATGTATTCATGAAA-3’ and reverse primer 5’-
ATATATCTTAAGGTCGACCTATGCGGCCCATTCAG-3’ (Stratagene: QuikChangeTM Site-
Directed Mutagenesis Kit). Triple tyrosine to phenylalanine mutations Y125F, Y133F, and 
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Y136F were generated by single nucleotide substitution of TAT to TTT (Y125F and Y133F) and 
TAC to TTC (Y136) using synthesized oligonucleotides as previously described Negro 2002 371. 
The vectors were verified by sequencing at Eurofins MWG Operon using standard CMV 
primers. 
 
Yeast strains cultures and determination of cell survival 
Genotypes of yeast strains and plasmid used are listed in Table 2. Wild-type W303.1a yeast 
strain cultures were transformed using standard lithium acetate protocol 459. All strains were 
grown in Synthetic complete medium without histidine and uracil (SC –His –Ura) for plasmids 
selection [6.7 g l–1 Yeast Nitrogen Base (BD Biosciences), appropriate amino acid dropout mix 
(Sunrise Science Products), 1% (w/v) raffinose or 1% (w/v) galactose]. Yeast strains carrying 
the galactose-inducible aSyn construct were pre-grown in raffinose medium (no repression of 
the galactose-inducible promoter) prior to galactose medium, to allow synchronous induction of 
expression.  
Yeast cells carrying the galactose-inducible aSyn-GFP construct alone or in combination with 
PLKs or kinased selected from the ORF library, were pre-grown in SC-His-Ura 1% raffinose for 
24 h, then diluted back in order to reach an optical density (OD600) of 0.1 after an overnight 
growth. For growth assays on solid medium, the cell suspensions were adjusted to 
OD600nm=0.05±0.005 and used to prepare 1/2 serial dilutions that were applied as spots (4 µl) 
onto the surface of the solid medium either with SC-His-Ura 1% glucose (control) or SC-His-
Ura 1% galactose (induced aSyn and kinases expression) as carbon source. The plates were 
then incubated at 30°C for at least 48 h. 
 
Table 2. Genotypes of the yeast strain and the plasmids used in this study. 
Yeast Strains Genotype 
W303.1a MATa strain (leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15). 
 
Plasmids Type of Plasmid 
p423GAL-aSyn-GFP 2 μ 
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p426GAL-aSyn-GFP 2 μ (This study) 
p423GAL-PLK1-GFP 2 μ (This study) 
p423GAL-PLK2-GFP 2 μ (This study) 
p423GAL-PLK2-GFP 2 μ (This study) 
p423GAL-PLK4-GFP 2 μ (This study) 
pGB1805-KinaseX-HA-FLAG 2 μ (Thermo Fisher Scientific Inc.) 
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Yeast functional screening 
Yeast kinases homologous to human ones as described in literature 460 were analysed using P-
POD: Princeton Protein Orthology Database (ppod.princeton.edu). A kinase list based on % of 
protein identity was genereated using NCBI protein Basic Local Alignment Search Tool 
(pBLAST; blast.ncbi.nlm.nih.gov). The thirteen kinases chosen for the screening were selected 
combining protein functional conservation (pBLAST value), brain expression and previous 
studies published in the PubMed catalog. The corresponding expression vectors were collected 
from in-house yeast ORF (open reading frame) library of plasmids 461. Each ORF has been 
Gateway-cloned into vector pGB1805 in frame with a C-terminal triple affinity tag comprised of 
6xHis-HA-C, under control of a galactose-inducible promoter (Thermo Fisher Scientific Inc.,) 
and –Ura as auxotrophic marker. Vectors, containing the selected kinases, were extracted 
using a standard miniprep kit (NZYTech, Lda. INOVISAN, Lisbon, Portugal), and then 
transformed together with the yeast expression vector p423GAL (-His as auxotrophic marker). 
Human aSyn was expressed under a galactose-inducible promoter and fused with GFP (see 
section “Cloning of PLKs, aSyn, and synphilin-1”) 434. aSyn and the selected kinases were 
transformed in the yeast strain W303.1a, using a standard lithium acetate protocol (H. Ito, Y. 
Fukuda, K. Murata, A. Kimura, J Bacteriol 153, 163, 1983). The cells were then grown and 
spotted onto SC-His-Ura 1% galactose or SC-His-Ura 1% glucose (control) agar plates (as 
described in the “Yeast strains cultures and determination of cell survival” section). Modifiers of 
aSyn toxicity were identified after incubation at 30°C for at least 48 h. 
  
Cell culture and transfections 
Mouse CAD cathecolaminergic cells (kind gift from Prof. C. Zurzolo, Instituto Pasteur, Paris) 
and Human H4 neuroglioma cells (HTB-148; ATCC, Manassas, VA, USA) were maintained in 
OPTI-MEM (Gibco/Invitrogen corporation, Carlsbad, CA, USA) supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomicyn, at 37°C under 5 % CO2.  
CAD cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and H4 
cells with FugeneTM 6 (Roche, Mannheim, Germany) according to the manufacturer’s 
instructions. For immunocytochemistry studies CAD and H4 cell were transfected in 5 cm dish 
using 0.5 μg of each plasmid DNA per dish. For immunoblotting analysis CAD cells were 
transfected in 6 well plates using 1 μg of each plasmid DNA per well, while H4 cells were 
transfected in 10 cm dish using 8 μg of each plasmid DNA per dish. All transfections in CAD 
and H4 cells were carried out in OPTIMEM + 10 % FCS without penicillin/streptomycin. 
 
Oligodendroglial immortal cell line (OLN WT) is derived from primary Wistar rat brain glial 
cultures 244. Cells were cultured at 37°C under 5 % CO2 in Dulbecco’s Modified Eagle’s 
46 
 
Medium (DMEM) (Lonza) supplemented with 10 % fetal calf serum (FCS), 50 U/ml penicillin, 
and 50 μg/ml Streptomycin (Gibco BRL). Transient transfection of OLN cell lines for 
immunoblotting studies was carried out in 6-well plates using FugeneTM 6 (Roche, Mannheim, 
Germany) according to the manufacturer’s instructions, using 0.45 μg of each plasmid DNA per 
well. For immunocytochemistry studies OLN cells were transfected in 12-well plates using 0.25 
μg of each plasmid DNA per well. For MTT studies OLN cells were transfected in 96-well plates 
using 0.05 μg of each plasmid DNA per well. All transfections in OLN cells were carried out in 
DMEM + 0,5 % FCS without penicillin/streptomycin. 
 
Compound treatment of transfected H4 cells 
H4 cells were stably transfected with GN-link-aSyn+aSyn-GC as previously described (outeiro 
TF 2008).  The PLK2 inhibitor BI2536, APMU (N-[4-(4-aminothieno[2,3-d]pyrimidin-5-
yl)phenyl]-N’-(3-methylphenyl)urea), was a kind gift from Prof. Poul Henning Jensen, Institut for 
Biomedicin – Medicinsk Biokemi, Aarhus Universitet. The inhibitor was diluted in DMSO at a 
final concentration of 1mM and cells were treated for 2 h, at a final concentration of 1 µM.  
 
Peptide and tyrosine inhibitors treatment of OLN cells 
CTSA and CT peptides were designed by Poul Henning Jensen, Institut for Biomedicin – 
Medicinsk Biokemi, Aarhus Universitet, and produced by Schafer-N, Copenhagen, Denmark. 
They both correspond to the last 40 aminoacid of aSyn full length protein (100-140). CTSA 
compared with CT present a substitution in position 129 where an alanine is placed instead of 
serine (H-
MRGSHHHHHHGMARGYGRKKRRPASPGASGKNEEGAPQEGILEDMPVDPDNEAYEMPA/S
EEGYQDYEPEA-OH); this modification mimics the non-phosphorylated state of aSyn. The 
peptides present also a TAT domain to permeate cell membranes and a poly-His tag for 
purification studies. The peptides were dissolved in Dulbecco’s Modified Eagle’s Medium 
(DMEM) at a final concentration of 2 mg/ml and used at a working concentration of 5 μM.  
For tyrosine inhibitors treatment 20.000 OLN WT cells were plated in each well of a 12 well-
plate and 1 cover slip was added on each well. OLN cells were transfected as described in 
section “Cell culture and transfections”. The kinase inhibitor and the vehicle control (DMSO) 
were added 4 h post-transfection at a final concentration of 5 μM. After 24 h coverslips were 
processed for immunocytochemistry. 
 
 
MTT assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) powder was dissolved 
in RPMI medium to a final concentration of 5 mg/ml and filtrated through 0,2 um filter. 5000 
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cells were plated per well in a 96 well-plate 24 h prior to transfection. 24 h post transfection 
(see Cell culture and transfections section) medium culture was removed and cells were gently 
washed with warm RPMI medium (Sigma Aldrich, St. Louis, MO, USA). 50ul of MTT solution 
(1:10 dilution of 5 mg/ml stock in RPMI medium) (Sigma Aldrich, St. Louis, MO, USA) was 
added per well and then incubated for 3 h in the cell incubator at 37 °C. 100 μl of lysis buffer 
(1% Triton X-100, 0.04 M HCl, diluted in isopropanol) was then added and the plated was 
incubated for 5 h on a shaking table at RT covered from light. Absorbance was measure at 570 
nm using 650 nm as a reference wavelength using VersaMax® microplate spectrophotometer 
(Molecular Devices, LLC, California, United States). 
 
Western blot analysis 
For quantitative analysis equal amount of yeast cells co-expressing aSyn and PLKs were taken 
8 h post-induction of aSyn expression, harvested and lysed in Tris-HCl buffer pH 7.4 with glass 
beads, in the presence of protease and phosphatases inhibitor cocktail (Roche, Mannheim, 
Germany). Cellular debris was spun down at 2,600 rpm for 5 min and supernatants containing 
total lysate were collected and sonicated (10 s at 10 mA, Soniprep 150 for Sanyo). Proteins 
were resolved by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotting 
was performed following standard procedures.  
 
Mouse CAD cathecolaminergic cells and human H4 neuroglioma cells were lysed with NP-40 
buffer 48 h post-transfection (Roche, Mannheim, Germany). Lysates were cleared from debris 
by a 13,000 rpm centrifugation for 30 s at 4°C and then subjected to sodium dodecylsulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and protein resolved on 10% (for PLKs) or 
12% (for aSyn) run at 300 V, 30-40 mA. After transfer to nitrocellulose membrane at 300 V, 250 
mA, 2 h, the membranes (Bio-Rad) were blocked for 1h at RT in bovine serum albumin BSA 
5% in TBS with 0.1% Tween, pH 7.4 (200 mM Tris-HCl pH 7.4, 500 mM NaCl) and then 
incubated in the same buffer using appropriate antibodies (listed below). Membrane were then 
washed 3 x 10 min in TBS with 0.1% Tween and incubated with horse radish peroxidase (HRP) 
labeled secondary antibodies. After washing three times in TBS with 0.1% Tween (TBS-T, pH 
7.4), immunoblots were developed using ECL (Millipore, Billerica, MA).  
 
Rat OLN oligodendroglial cells were harvested 24 h post transfection in 30 μl of RIPA buffer 
(50 mM Tris-Hcl, pH 7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2mM 
EDTA, 50mM NaF) in the presence of protease and phosphatases inhibitor cocktail (Roche, 
Mannheim, Germany). Lysates were centrifuged for 3 min at 5,000 rpm to pellet nuclei, subject 
to SDS-PAGE and protein resolved 4-15 % gradient gels run at 300 V, 30-40 mA. The proteins 
were electrically transferred to polyvinylidene fluoride membranes (GE Healthcare) at 300 V, 
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250 mA, 2 h. Blots were blocked for 1 h at RT in BSA 5% in TBS with 0.1% Tween (for 
phosphorylation studies) or in Milk 5% in TBS with 0.1% Tween, pH 7.4 (200 mM Tris-HCl pH 
7.4, 500 mM NaCl); incubated for 1 h at RT or overnight (ON) at 4 °C with appropriate primary 
antibody. Membranes were then washed 3 x 10 min in TBS with 0.1% Tween-1, and then 
incubated 1 h at RT in appropriate secondary antibody conjugated to (HRP). The blots were 
developed by enhanced chemiluminescence (Amersham ECL Western Blotting Detection 
Reagent, GE Healthcare) using a Fuji LAS-3000 Imager. The primary antibodies used are 
listed in Table 3.  
 
Immunocytochemistry and microscopy analysis 
Fluorescence microscopy of yeast cells was performed with a Zeiss Axiovert 200M Widefield 
Fluorescence microscope equipped with a digital Axiocam from Zeiss (Objective 100X, Plan-
Apochromat, Oil, NA (1.40)). Transformants expressing aSyn alone or with PLK2 or PLK3 were 
pre-grown on SC-His-Ura 1% raffinose as described above and then on SC-His-Ura 1% 
galactose medium for 8 h at 30°C with shaking. Yeast cells were subsequently spin down and 
visualized under the microscope. The proportion of cells presenting aSyn inclusions was then 
determined by counting at least 1000 cells per strain using ImageJ software. Significance was 
calculated using Student’s two-tailed unpaired t test. A value of p<0.05 was considered to be 
statistically significant. 
Transfected CAD cells were fixed with 4% paraformaldehyde in 140 mM NaCl, 10 mM Na-
phosphate pH 7.4 (PBS). Cells were permeabilized in PBS containing 0.1% Triton X-100 and 
blocked in 1.5% normal goat serum containing PBS for 1 h. Cells were incubated with primary 
antibody for 2 h at RT or overnight at 4°C (mouse anti-aSyn; BD Transduction Laboratories, 
San Jose, CA, USA; rabbit anti-Venus-synphilin-1; Sigma Aldrich, St. Louis, MO, USA) 
followed by secondary antibody incubation for 1 h (goat anti-mouse IgG-Alexa488 Invitrogen 
corporation, Carlsbad, CA, USA and a donkey anti-rabbit IgG-Alexa568, Invitrogen corporation, 
Carlsbad, CA, USA). Slides were subjected to fluorescence microscopy with a Zeiss Axiovert 
200M Widefield Fluorescence microscope equipped with a digital Axiocam from Zeiss 
(Objective 40X, EC Plan-NeoFluar, Dry, NA (0.75)). The proportion of cells with aSyn 
inclusions within the population was then determined by counting at least 100 cells per 
condition using ImageJ software. For BiFC-GFP reconstitution assay, H4 stable cell line 
expressing aSyn dimers/oligomers was bioimaged as previously described (ADDD)[22]. All 
data were analyzed using Student’s two-tailed unpaired t test. A value of p<0.05 was 
considered to be statistically significant. 
 
OLN cells were cultured on poly-L-lysin coated cover slips for 24 h and fixed in 4 % 
formaldehyde, PBS for 10 min. Cell membranes were permeabilized by 30 min incubation in 
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permeabilization buffer (50 mM glycine, 0.1 % Triton X-100, PBS) and were blocked in 3 % 
BSA, PBS for 30 min. Cells were then incubated in appropriate primary antibodies for 1 h 
(rabbit anti-aSyn, ASY-1 and rat anti-p25 in-house antibody, PH Jensen laboratory, 
Biomedicine Department, Aarhus; and mouse anti-tubulin, Sigma Aldrich, St. Louis, MO, USA), 
washed 3 x 5 min in PBS, incubated 1 h in appropriate fluorescently-labelled secondary 
antibodies (goat anti-rabbit IgG-Alexa488, goat anti-rat IgG-Alexa568 and goat anti-mouse IgG-
Alexa647, Invitrogen corporation, Carlsbad, CA, USA) and washed again. Nuclei were 
counterstained with DAPI included in the fluorescent mounting medium (DAKO, Denmark). 
Fluorescent signals were analyzed on a Zeiss Axiovert 200M inverted fluorescence microscope 
equipped with a camera (Objective 40X, EC Plan-NeoFluar, Dry, NA (0.75)). The microtubule 
retraction (MT) was quantified as the percentage of αSyn- and p25-positive cells with MT 
retraction. For each experiment, approximately 100-200 cells were counted for each condition. 
All data were analyzed using Student’s two-tailed unpaired t test. A value of p<0.05 was 
considered to be statistically significant.  
 
Sucrose velocity gradients 
Yeast spheroblasts were prepared with the following procedure: yeast cells expressing aSyn 
alone or together with PLK2 or PLK3 were harvested by centrifugation, washed with sterile 
water, suspended in spheroplasting solution (Tris pH 7.5 20mM, MgCl2 0.5mM, BME 50 mM, 
sorbitol 1.2 M and zymolyase 0.5 mg/ml) and incubated at 30ºC for 30 min. Samples were 
centrifuged at 800 g for 5 min at room temperature and the supernatant was completely 
removed. Yeast spheroplasts and CAD cells were lysate in a solution containing (Tris pH 7.4 
1M, NaCl 5M, SDS 0,4%, Triton X-100 0,2%) with inhibitors for 
proteases/kinases/phosphatases (Roche, Mannheim, Germany) and were placed 20 min on 
ice. Then, cells were mechanically disrupted by forcing the solution to pass through a 25G 
syringe 6 times. 1 mg of total protein was applied on a 5 to 30% sucrose gradient. 
Centrifugation was conducted at 4°C with a swinging bucket rotor (SW-55Ti rotor, Beckman 
Instruments, Co., Palo Alto, CA) in a Beckman XL-90 S/N ultracentrifuge at 450,000 rpm for 16 
h. Nine fractions were collected, precipitated for 4 h at 4°C in trichloroacetic acid. Proteins were 
then washed in acetone for three times and resuspended in protein sample buffer (0.5 M Tris-
HCl, pH 6.8, Glycerol, 10% (w/v) SDS, 0.1% (w/v) Bromophenol Blue), resolved by SDS-
PAGE, transferred to nitrocellulose membranes and immunoblotted against total aSyn following 
standard procedures. The velocity gradient procedure and estimation of the molecular sizes for 
each fraction were previously described 462. 
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Table 3. List of primary antibodies used in this study. 
Antigen and dilution used Source Producer 
Alpha-synuclein (aSyn) 
1:3000 (yeast studies) 
1:1000 (cell studies) 
Mouse BD Transduction Laboratories, San 
Jose, CA, USA 
Alpha-synuclein (aSyn) (ASY-1) 
1:1000 (OLN studies) 
Rabbit In-house, PH Jensen laboratory, 
Aarhus University 
phospho-Ser-129 aSyn 
1:3000 (yeast and cell studies) 
Mouse Wako Chemicals USA, Inc., 
Richmond VA, USA 
phospho-Tyr-125 aSyn 
several dilutions tested 
Rabbit Abcam, Cambridge, UK 
p25 
1:2000 (OLN studies) 
Rat In-house, PH Jensen laboratory, 
Aarhus University 
Venus-synphilin-1  
1:2000 (cell studies) 
Mouse Sigma Aldrich, St. Louis, MO, USA 
Myc-PLKs 
1:2000 (cell and yeast studies) 
Mouse Cell Signaling Technology, Inc., 
Danvers, MA 
GAPDH  
1:1000 (yeast studies) 
Mouse Ambion, Cambridgeshire, UK 
alpha-tubulin 
1:3000 (cell studies) 
Mouse Sigma Aldrich, St. Louis, MO, USA 
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4. Results 
 
4.1. The role of PLK2 on alpha-synuclein aggregation in yeast 
 
To better understand the function of aSyn phosphorylation, we took advantage of the yeast 
system to study the molecular effects of Ser-129 phosphorylation on aSyn toxicity and inclusion 
formation. The Saccharomyces cerevisiae yeast strain W303.1a was transformed with human 
aSyn-GFP cloned into a 2µ vector, under the regulation of a galactose inducible promoter. In 
these strains, expression of aSyn is moderately toxic to cells, as previously described 434. Since 
several studies identified PLKs as one of the most important kinases family involved in aSyn 
phosphorylation 331, the same strain was then transformed with the four members of human 
PLKs. PLKs-myc were also cloned in a 2µ vector, under galactose promoter. 
We determined the levels of Ser-129 phosphorylation by immunoblotting. As previously 
described, co-expression of aSyn with PLK2 and PLK3 resulted in a pronounced increase in 
the levels of aSyn Ser-129 phosphorylation, while PLK4 had no significant effect (Fig. 13A). 
PLK1 blot band was much lower compared to the other kinases (Fig. 13A), probably either due 
to its low protein expression levels or higher insolubility, precluding further studies on the effect 
of this kinase on aSyn phosphorylation; therefore, we focused on PLK2 and PLK3. 
Initially, we investigated whether PLK2 or PLK3 altered the cytotoxicity induced by aSyn in our 
yeast model. Using spotting assay, we found that co-expression of PLK2 with aSyn reduced 
cell growth, while PLK3 had no effect (Fig. 13B).  
Next, we investigated whether PLK2-induced toxicity was associated with the formation of 
intracellular inclusions. Interestingly, while 50% of the cells expressing aSyn alone formed 
fluorescent foci (Fig. 13C), co-expression of PLK2 resulted in a 10% increase of foci-positive 
cells (Fig. 13C). Remarkably, PLK3 although able to increase aSyn phosphorylation on Ser-
129, did not affect either the percentage of cells bearing aSyn foci or cell growth. 
Thus, to establish the role of PLK2 mediated phosphorylation on aSyn toxicity and inclusion 
formation, experiments were carried out in the presence of a kinase dead mutant (DM) of 
PLK2, carrying a K111M substitution 463. As expected, the PLK2 kinase dead mutant 
(PLK2DM) prevented the phosphorylation on Ser-129 without affecting the levels of aSyn (Fig. 
13D). We then tested the effect of PLK2DM on the cytotoxicity of aSyn by spotting assays, and 
we detected a decrease in cell growth, as observed for the WT PLK2 protein. We next asked 
whether PLK2DM co-expression affected the distribution of aSyn in yeast cells.  Surprisingly, 
we did not observe any difference in the percentage of cells with aSyn foci compared with the 
one co-expressing WT PLK2 (Fig. 13C). We then analyzed aSyn co-expression with PLK4, a 
member of the PLK family that was unable to increase aSyn phosphorylation levels on Ser-129 
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(Fig. 13A). We found that PLK4 co-expression did not alter aSyn foci formation and toxicity (Fig 
13F).  
Altogether these results demonstrate that the phenotype observed is not only correlated with 
aSyn phosphorylation on Ser-129 but it is specific for PLK2; suggesting that the role of PLK2 
on aSyn inclusion formation and toxicity might result from additional effects that are not solely 
dependent on PLK2 kinase activity and, consequently, on the direct phosphorylation of aSyn 
on Ser-129.  
Next, in order to assess the biochemical state of aSyn-GFP in the fluorescent foci we 
performed ultracentrifugation analysis in sucrose gradients. We observed an increase in the 
levels of aSyn species with higher molecular weight in cells co-expressing PLK2, PLK2DM and 
PLK3 (Fig. 13E). PLK2DM promoted the accumulation of similar types of aSyn-GFP species to 
those formed in the presence of PLK2 (Fig. 13E), confirming that the effect of PLK2 on aSyn 
inclusion formation is independent from its ability to phosphorylate aSyn on Ser-129. 
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Figure 13. PLK2 increases aSyn Ser-129 phosphorylation, cytotoxicity and foci formation in 
yeast. A. Phosphorylation levels of aSyn on Ser-129 (pSER129) when expressed either alone (aSyn + 
empty vector (EV)) or with PLK1 (68 kDa), PLK2 (78 kDa), PLK3 (71 kDa) and PLK4 (104 kDa) 
determined by immunoblotting (left panel). pSER129 overexposed blot showing phosphorylation levels in 
all the conditions examined. Densitometric analysis of the immunodetection of aSyn Ser-129 
phosphorylation levels were normalized for the total amount of aSyn (mean ± s.e.m.) and relative to the 
aSyn + EV condition (upper panel). B. Spotting assay of yeast cultures co-expressing aSyn (aSyn + EV) 
or empty vector (EV) with PLK2 or PLK3 or PLK2DM (dead kinase mutant version of PLK2). C. 
Fluorescence microscopy and quantification of the number of cells presenting aSyn foci in cells 
expressing aSyn-GFP fusion protein alone (aSyn-GFP + EV) or together with PLK2, PLK3 or PLK2DM. 
D. Phosphorylation levels of aSyn on Ser-129 when expressed either alone (aSyn + EV) or together with 
either PLK2 or PLK2DM determined by immunoblotting (upper panel). Densitometric analysis of the Ser-
129 phosphorylation levels normalized for the total amount of aSyn (mean ± s.e.m.) (upper right panel).  
E. The oligomeric species formed in yeast cells expressing aSyn alone (aSyn + EV) or with PLK2 or 
PLK2DM or PLK3 were resolved using sucrose gradients. The resulting fractions were applied to a SDS-
page gel followed by immunoblotting with an antibody anti-aSyn (lower panel). F. Spotting assay of yeast 
cultures co-expressing aSyn (aSyn + EV) or empty vector (EV) with PLK4. Fluorescence microscopy and 
quantification of the number of cells presenting aSyn foci in cells expressing: aSyn-GFP alone (aSyn-
GFP + EV) or together with PLK4. All the data shown are representative of at least three independent 
experiments. Statistical analysis was performed using two-tailed Student’s t test for unpaired data 
(*=p<0.05, **=p<0.005). 
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4.2. The role of PLK2 on alpha-synuclein aggregation in mammalian cell models 
of PD 
 
In order to validate the results obtained in yeast, we investigated the effect of PLK2 on aSyn 
oligomerization in a neuroglioma human cell line (H4 cells). First, we assessed the effect of 
PLK2 on aSyn oligomerization using bimolecular fluorescence complementation assay (BiFC) 
(Fig. 14A) 186. Cells stably expressing the aSyn BiFC constructs were transfected with PLK2 
and analyzed by fluorescence microscopy (Fig. 14A). The overall fluorescence of the cells was 
not changed in the presence of PLK2. However, in 10% of the cells co-expressing PLK2 we 
observed the presence of punctate foci, suggesting oligomers were recruited into larger 
inclusions (Fig. 14A). We then investigated the role of PLK2 on inclusion formation using the 
BI2536 PLK2 inhibitor 330. This treatment eliminated aSyn inclusions (Fig. 14B). In parallel, we 
evaluated aSyn expression levels as well as Ser-129 phosphorylation levels by immunoblotting 
analysis. As expected, we detected a significant increase in aSyn Ser-129 phosphorylation in 
the presence of PLK2, while treatment with BI2536 reduced phosphorylation (Fig. 14B), 
indicating that the BI2536 PLK2 inhibitor was effective.  
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Figure 14. PLK2 does not interfere with aSyn oligomerization. A. Microscopy analysis of H4 cells 
stably transfected with GN-link-aSyn+aSyn-GC and transiently co-transfected either with PLK2 or an 
empty vector (EV), in the presence (BI2536) or absence (DMSO) of a kinase inhibitor. aSyn fluorescence 
intensity is quantified in arbitrary units. The percentage of cells with aSyn inclusions is shown. B. H4 
cells stably transfected with GN-link-aSyn+aSyn-GC were immunoblotted 48 h post transient co-
transfection either with PLK2 or empty control (EV), in the presence (BI2536) or absence (DMSO) of a 
kinase inhibitor, using antibodies against aSyn phosphorylated on Ser-129 and total aSyn. Ser-129 
phosphorylation levels were normalized for the total amount of aSyn (mean ± s.e.m.) and relative to the 
EV + DMSO condition. All data presented are representative of three independent experiments. 
Statistical analysis was performed using two-tailed Student’s t test for unpaired data (*=p<0.05), 
(**=p<0.005). 
 
To further confirm the effect of PLK2 on aSyn aggregation propensity, we used another 
mammalian cell system. PLK2 was co-expressed with aSyn and synphilin-1, an established 
paradigm of aSyn aggregation which results in the formation of LB-like inclusions 183. Synphilin-
1 is a known aSyn interacting protein 13, present in the core of LBs 464. A cathecolaminergic 
mouse cell line (CAD) was co-transfected with aSyn and synphilin-1 together with each of the 
four PLKs. We then evaluated the levels of aSyn and Ser-129 phosphorylation by 
immunoblotting analysis. Both PLK2 and PLK3 induced aSyn Ser-129 phosphorylation while 
PLK1 had no effect (Fig. 15A). The lower expression levels of PLK4 precluded further 
conclusions on the effects of this kinase (Fig. 15A).  
Interestingly, co-expression of aSyn with PLK3, but not PLK2, resulted in a significant reduction 
in the levels of aSyn (Fig. 15A), in agreement with previous studies 334. Thus, it was not 
possible to further evaluate the role of PLK3 on aSyn phosphorylation or aggregation using this 
cell model.   
Next, we investigated the effect of PLK2 on aSyn aggregation by immunocytochemistry. We 
found that PLK2 slightly altered the percentage of cells displaying aSyn inclusions, although 
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this did not reach statistical significance (Fig. 15B). Nevertheless, the accumulation of larger 
aSyn inclusions was observed in the presence of PLK2, confirming an effect on aSyn 
aggregation propensity (Fig. 15B).  
To assess the biochemical nature of the aSyn aggregates formed in the presence of PLK2, we 
performed ultracentrifugation in sucrose gradient. In agreement with the data obtained in yeast, 
we observed an increase of aSyn higher order oligomeric species (Fig. 15C). 
 
  
Figure 15. PLK2 induces aSyn phosphorylation and increases the size of aSyn aggregates in 
CAD cells. A. CAD cells were transiently transfected with aSynEGFP∆155 (aSynT + EV), synphilin-1 
and PLK1, PLK2, PLK3 and PLK4. Cells were lysed and immunoblotted for phosphorylated aSyn, total 
aSyn, synphilin-1 and PLKs (myc-tag). Ser-129 phosphorylation levels were normalized for the total 
amount of aSyn (mean ± s.e.m.) and relative to the aSynT + EV. B. aSynT (aSynEGFP∆155), 
synphilin-1 and PLK2 expressing cells were immunostained for aSyn and synphilin-1. The number of 
cells containing aSyn aggregates is plotted as a percentage of total transfected cells and relative to 
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the aSynT + EV condition. C. Lysates of CAD cells expressing aSynT (aSynEGFP∆155) alone or with 
PLK2 were ultracentrifuged in sucrose gradient and analyzed by immunoblotting using antibodies 
against aSyn phosphorylated on Ser-129 and total aSyn. All data presented are representative of 
three independent experiments. Statistical analysis was performed using two-tailed Student’s t test for 
unpaired data (**=p<0.005). 
 
The results described in the section 4.2 are part of the following pubblication:  
 
Basso E., Antas P., Marijanovic Z., Gonçalves S., Tenreiro S. and Outeiro TF. “PLK2 
modulates a-synuclein aggregation in yeast and mammalian cells”. Mol Neurobiol. 2013 May 
17. 
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4.3. Yeast functional screening to identify novel kinases involved in alpha-
synuclein pathobiology 
 
The yeast kinome 460 was analyzed using the P-POD: Princeton Protein Orthology Database 
(as described in materials and methods section). This is a database system that permits to find 
the phylogenetic relationships among orthologs to a query gene, and visualize them in an 
evolutionary context. The database displays also results collected from the literature linking to 
relevant human disease and gene information via the OMIM, model organisms, and sequence 
databases. 
17 kinases were selected according to three features:  functional conservation with human 
orthologous, expression in the nervous system and previous data available in the PubMed 
catalogue (Table 4). Among the selected kinases ATG1, KNS1 and NRK1 were included since 
they were found differently expressed in yeast strains expressing aSyn WT compared to aSyn 
S129A phosphorylation mutant (microarray analysis performed by Sandra Tenreiro in our 
laboratory): ATG1 and KNS1 were up-regulated in the S129A mutant compared to the WT, 
while NRK1 was down-regulated. After retrieving the corresponding plasmids from our ORF 
library 461, the yeast strain W303.1a was transformed with aSynWT-GFP, cloned into a 2µ 
vector under the regulation of a galactose inducible promoter, and each of the 17 kinases or 
the corresponding empty vector. The kinases-HA tagged were also cloned in a 2µ vector, 
under galactose promoter. 
The screen to assess the kinases effect consisted of three main assays: 
1. Growth assay: using spotting assay (a previously described phenotypic assay). 
2. Immunoblotting analysis: protein expression and aSyn phosphorylation on Ser-129 was 
evaluated by SDS-PAGE. 
3. aSyn-GFP foci: the number of cells presenting aSyn-GFP positive inclusions was 
quantified by microscopy 8 hours post induction of expression. 
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Table 4. Yeast kinases selected for the functional screening. 
Yeast Kinases Protein 
Identity 
(pBLAST) 
Human orthologous Expression Reference 
DUN1 
CAMK family 
37% Serine/threonine-protein kinase 
CHK2 
Ubiquitous  
465
 
PKH2 
PKA related family 
46% 3-phosphoinositide-dependent 
protein kinase 1 (PDK1) 
Ubiquitous 
466, 467
 
SKY1 
CLK family 
35% Serine/threonine-protein kinase 
SRPK1 
Highly expressed 
in brain 
468
 
CDC28 
CDK family 
98% Cyclin-dependent kinase 2 Ubiquitous 
469
 
BUD32 99% TP53 regulating kinase 
(TP53RK) 
Ubiquitous 
470
 
NRK1 
PAK/Ste20 family 
54% Serine/threonine-protein kinase 
24 
Isoform A: 
Ubiquitous 
Isoform B: Brain 
471
 
ATG1 
ATG family 
34% Serine/threonine-protein kinase 
ULK1 
Ubiquitous 
472
 
IPL1 
AUR family 
44% Serine/threonine-protein kinase 
aurora-A 
Found at the 
neuritis hillock in 
developing 
neuron. 
473
 
SNF1 
AMPK family 
41% 5'-AMP-activated protein kinase 
catalytic subunit alpha-1 and 
alpha-2 
Ubiquitous 
474
 
CBK1 
nuclear Dbf2-related 
(NDR) family 
48% Serine/threonine-protein kinase 
38-like 
Ubiquitous 
475
 
KNS1 
CLK family 
40% Dual specificity protein kinase 
CLK4 
Expressed in liver, 
kidney, heart, 
muscle, brain and 
endothelial cells 
476
 
SLT2 
MAPK family 
43% Mitogen-activated protein kinase 
7 
Adult tissue 
477
 
HOG1 
MAPK family 
52% Mitogen-activated protein kinase 
2 
Brain, heart, 
placenta, 
pancreas and 
skeletal muscle. 
Expressed to a 
lesser extent in 
lung, liver and 
kidney 
478
 
FUS3 
MAPK family 
50% Mitogen-activated protein kinase 
3 
Ubiquitous 
479
 
KIN28 
CDK family 
48% Cell division protein kinase 7 Ubiquitous 
480
 
KSS1 
MAPK family 
50% Mitogen-activated protein kinase 
1 
Ubiquitous 
481
 
PBS2 
STE7 family 
42% Dual specificity mitogen-
activated protein kinase kinase 1 
Ubiquitous 
482
 
 
After performing the spotting assays,, two kinases consistently showed a significant increase 
in growth impairment compared with the condition in which solely aSyn was expressed: Atg1 
and Sky1 (Fig. 16B). Atg1 is a Ser/Thr kinase required for the cytoplasm to vacuole targeting 
pathway (Ctv), whose over-expression is used as a model to induce autophagy both in yeast 
and mammalian cell lines 483. Sky1 is a Ser/Thr kinase regulating proteins involved in mRNA 
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metabolism 484. Conversely, only one kinase reverted the phenotype, Pkh2, augmenting 
yeast cell growth in aSyn dependent manner (Fig. 16B). Pkh2 is a Ser/Thr kinase involved in 
sphingolipid-mediated signaling pathway that controls endocytosis and activates signaling 
cascade components required for maintenance of cell wall integrity 485, whereas the human 
homologous is involved in insulin signaling pathway 466. 
We next performed immunoblotting analysis to characterize aSyn phosphorylation levels on 
Ser-129. Data demonstrated that none of the 17 kinases seem to significantly affect aSyn 
phosphorylation (Fig. 16A,C). Furthermore expression of Hog1 and Pkh2 was not detected, 
thus the phenotype observed with Pkh2 might not be associated with the kinase in study. 
Nonetheless, for the other kinases studied, further experimental data are necessary to 
evaluate phosphorylation levels of other aSyn known residues, such as Ser-87 or Tyr-125. 
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Figure 16. Atg1 and Sky1 decreases aSyn yeast dependent cell growth, while PKH2 increases 
it A. Immunoblotting analysis of total and aSyn phosphorylated on Ser-129 co-expressed with empty 
vector (aSyn + EV) or with the indicated kinases after 8 hours of expression induction. Kinases 
expression was detected using an antibody against HA flag. Correspondent MW is indicated by 
arrows, where absent, the specific kinase was not detected or the MW was not the predicted one. B. 
Spotting assay of yeast cultures co-expressing aSyn (aSyn + EV) or empty vector (EV) with 17 
different kinases selected for the screening. C. Densitometric analysis of the immunodetection of 
aSyn Ser-129 phosphorylation levels were normalized for the total amount of aSyn (mean ± s.e.m.) 
and relative to the aSyn + EV condition. All the data shown are representative of two independent 
experiments. 
 
Next, we investigated whether any of the kinases affected the formation of aSyn foci. It has 
been previously established that 50% of the cells 8 hours post induction of aSyn expression 
(cloned in a 2µ vector) form fluorescent foci (Fig. 17). Outstandingly, none of the kinases 
analyzed increased significantly the number of cells bearing aSyn foci (Fig. 17), while Dun1, 
Sky1 and Cdc28 decreased it significantly. Sky1 expression in particular, decreases both 
yeast growth and foci formation; anyway further experimental data will be necessary to 
establish a potential correlation between the two phenotypes observed. Additional data will 
aim to characterize which types of aSyn species are being formed or will evaluate possible 
differences in the number of foci per cell or their size. 
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Altogether these data produced useful information to further investigate two new kinases, 
Atg1 and Sky1, involved in aSyn pathobiology.  
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Figure 17. Cells bearing aSyn foci upon co-expression with the selected kinases. 
Representative fluorescence images of cells expressing aSyn alone (aSyn-GPF + EV) or with the 
selected kinases (top panel). On the bottom, percentage of cells presenting aSyn foci in cells co-
expressing aSyn-GFP fusion with empty vector (aSyn-GFP + EV) or with the indicated kinases. All 
the data shown are representative of two independent experiments. Statistical analysis was 
performed using two-tailed Student’s t test for unpaired data (*=p<0.05). 
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4.4. The role of alpha-synuclein phosphorylation on microtubule retraction in 
oligodendroglial cells 
 
To model the molecular events underlying MSA, we used a cellular model based on the co-
expression of aSyn and p25 in the rat OLN WT oligodendrocyte cell line 246. Co-expression of 
these two proteins promotes microtubule dysfunction within 24 h and rounding up of the cell 
that ultimately leads to activation of apoptotic processes. This result represents a combined 
effect aSyn-specific and p25 because expression of either aSyn or p25 alone does not induce 
any disruption of the MT network. The authors then addressed the role of Ser-129 
phosphorylation using a mutant that mimics the non-phosphorylated S129A state of the protein 
(SA). The SA mutant prevented MT retraction and cell degeneration 246. Furthermore, the role 
of a known aSyn aggregation inhibitor, ASI-1D 486 was assessed. ASI-1D was identified based 
on a library compound screening and comprises mainly the NAC region of aSyn; treatment with 
ASI-1D reduced MT retraction, indicating that aSyn aggregation is involved in the observed 
phenotype 246.   
To assess the role of tyrosine phosphorylation in the above oligodendroglial cellular model, we 
constructed two different phosphorylation mutants: aSynSAYF and aSynYF. In these 
constructs three tyrosine residues in position 125, 133 and 136 were mutated to a 
phenylalanine, a substitution that by removing a hydroxyl group mimics the non-phosphorylated 
state of the protein. We evaluated the effect on MT retraction 24 h post transfection by 
immunostaining (Fig. 18A). Our data demonstrated that the absence of phosphorylated 
tyrosine residues disrupted the protection induced by the aSynSA mutant (Fig. 18B), 
suggesting an important role for tyrosine phosphorylation in this model. Moreover, the 
percentage of cells displaying MT retraction reached the same value of aSyn WT condition, 
further corroborating the importance of available aSyn tyrosine residues in the microtubule 
dynamics and in the cellular architecture. We then performed immunoblotting analysis to 
determine protein expression levels (Fig. 18C). We noticed that aSynYF expression levels 
were lower compared to the others proteins; we hipothezied that this mutant may form higher 
insoluble aSyn species. Conclusively, tyrosine residues in the C-terminal of aSyn are involved 
in the degenerative phenotype in the oligodendroglial model co-expressing aSyn and p25. 
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Figure 18: Removal of aSyn C-terminal tyrosine residues abrogates the protective effect of 
aSyn SA mutation. A. OLN WT cells transiently transfected with aSyn+ EV (empty vector) or p25, 
aSynSA + p25, aSynYF + p25, aSynSAYF + p25 and subjected to immunofluorescence microscopy 
using anti aSyn (green), alpha-tubulin (purple) and anti-p25 (red) antibodies. The MT retraction from 
processes to the perinuclear region upon co-expression of p25 and aSyn is evident (arrows). Note 
the absence of MT retraction in aSyn + EV and EV + p25 transfected OLN WT cells.  B. Cellular 
degeneration is quantified as percentage of aSyn and p25 transfected cells presenting MT retraction 
in OLN WT cells transiently transfected with aSyn+ EV (empty vector) or p25, aSynSA + p25, 
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aSynYF + p25 and aSynSA-YF + p25. Bars represent the mean ± S.D C. OLN WT cells transiently 
transfected with aSyn + EV (empty vector) or p25, aSynSA + p25, aSynYF + p25 and aSynSA-YF + 
p25 were immunoblotted 24 h post transfection using antibodies against total aSyn and tubulin. All 
data presented are representative of at least three independent experiments. 
 
To test if the unfolded C-terminal of aSyn could be involved in the phenotype observed 
(independently from the N-terminal region), we developed a strategy to treat cells with a 
cell-penetrating peptide mirroring this domain. The novel designed peptide was named 
CTSA (Fig. 19A). CTSA corresponds to the C-terminal domain of aSyn bearing an 
aminoacid substitution in position 129, where a serine residue is mutated to an alanine 
residue. It is fused to a TAT domain to favor cell penetration and a hexa-histidine tag to 
allow for affinity purification (Fig 19A). The peptide was designed to mirror the conditions in 
which the MT retraction is rescued; which is when aSynSA is co-expressed with p25. 
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Figure 19. Effects of a cell penetrating peptide mirroring aSyn C-terminal. A. CTSA is a newly 
designed peptide corresponding to the C-terminal domain of aSyn. The peptide corresponds to the 
last 40 aminoacid of aSyn in which a serine in position 129 is substitute to an alanine (S129A). 
Additionally, in the N-terminal were incorporated a TAT domain and a poly-HIS tag. B. Cell 
permeability was tested in OLN WT cells 30 minutes after adding the peptide (5 µM) in the media, 
cells were fixed and stained for aSyn using ASY-1 antibody (green). Confocal microscopy shows a 
clear staining only in cells treated with the peptide. C) The effect of CTSA or vehicle control (CTR) was 
tested on MT retraction in the OLN aSyn + p25 model for three different concentrations, respectively 1, 
5 and 10 µM. At 5 µM a marked decrease on MT retraction is already visible. Cellular degeneration is 
quantified as percentage of aSyn and p25 transfected cells presenting MT retraction. The 
experimental conditions were performed once D. Possible toxic effect of CTSA peptide or vehicle 
control (CTR) was tested in non-transfected and transfected cells at three different concentrations (1, 
5 and 10 µM) by MTT assay. No toxicity was detected at any of the indicated concentrations. MTT 
assay was performed and quantified as described in Materials and Methods. Bars represent the mean 
± S.D. All data are representative of at least three independent experiments, unless otherwise stated. 
 
CTSA peptide is able to permeabilize the cells within 30 minutes after its addition to the 
culture media (Fig. 19B). To determine the optimal working concentration, we tested three 
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different peptide concentrations: 1, 5 and 10 µM. We then evaluated the effect on MT 
retraction in oligodendroglial cells expressing aSyn alone, p25 alone and aSyn together with 
p25, by immunocytochemistry; and the potential toxicity of the peptide by MTT assay (Fig. 
19C). Both at 5 and 10 µM it was evident that CTSA is able to decrease the percentage of 
cells retracting their microtubules when co-expressing aSyn and p25 and no toxicity was 
detected both in transfected and non-transfected conditions (Fig. 19D). Since we already 
detected a significant decrease in MT retraction at 5 µM, then we selected this concentration 
for the study. We added CTSA 4 h post transfection and we performed immunostaining 
analysis 24 h post transfection (Fig. 20A). The data showed that CTSA is able to reduce the 
p25 dependent MT retraction in the presence of aSyn WT and aSynSAYF, but it does not 
further rescue the phenotype of the non-toxic aSynSA mutant (Fig. 20A). Next, we assessed 
protein expression and phosphorylation levels on Ser-129 by immunoblotting (Fig. 20B). No 
major differences were detected between control and treated samples. Although CTSA is 
also able to decrease MT retraction in presence of the aSynYF mutant, the low protein 
expression levels of this mutant do not allow any conclusions. 
Conclusively, the non-phosphorylated Ser-129 aSyn C-terminal can independently of the rest 
of the aSyn molecule attenuate the toxicity of aSyn and p25 co-expression in our 
oligodendroglial model of MSA.  
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Figure 20. CTSA peptide protect both against cell stress elicited by aSyn WT and aSynSAYF. A. 
OLN WT cells transiently transfected with aSyn+ EV (empty vector) or p25, aSynSA + p25, aSynYF + 
p25 and aSynSA-YF + p25 in the presence (CTSA) or absence (vehicle control - CTR) of a novel 
peptide for 24 h and subjected to immunofluorescence microscopy using anti aSyn and anti-p25 
antibodies. The MT retraction upon co-expression of p25 and aSyn is evident (arrows) and it is 
rescued by CTSA peptide when aSyn+p25, aSynYF + p25 and aSynSAYF are co-expressed. On the 
right cellular degeneration is quantified as percentage of aSyn and p25 transfected cells presenting 
MT retraction in OLN WT cells transiently transfected with aSyn + EV (empty vector) or p25, aSynSA + 
p25, aSynYF + p25 and aSynSAYF + p25 in the presence (CTSA) or absence (vehicle treatedl - CTR) 
of a novel peptide. Bars represent the mean ± S.D. B. OLN WT cells transiently transfected with a 
aSyn + EV (empty vector) or p25, aSynSA + p25, aSynYF + p25 and aSynSAYF + p25 were extracted 
in RIPA buffer (see materials and methods) 24 h after transfection and analyzed by immunoblotting, in 
the presence (CTSA) or absence (vehicle treated - CTR) of a peptide, using antibodies against aSyn 
phosphorylated on Ser-129, total aSyn and tubulin. Densitometric analysis of the immunodetection of 
aSyn Ser-129 phosphorylation levels were normalized for the total amount of aSyn (bars represent 
mean ± S.D), while aSyn total levels were normalized for tubulin levels (loading control). All data 
presented are representative of three independent experiments. 
 
To further characterize if the effect of the CTSA peptide on MT retraction was dependent on 
the SA substitution, we produced a control peptide representing the native C-terminal of 
aSyn, without the SA exchange, and named CT. Similarly to the previous experiments, we 
tested a concentration of 5 µM on MT retraction, toxicity and permeability (Fig. 21). The 
peptide behaved like the CTSA peptide by being able to permeabilize the cells within 30 
minutes (Fig. 21A), and did not display toxicity to the cells as shown by MTT assay (Fig. 
21A). Remarkably it did not affect MT retraction (Fig. 21B). These results demonstrate the 
beneficial properties of the CTSA peptide and suggest -by analogy to full length aSyn- that 
this could be due to the removal of the serine 129 phosphorylation residue. In fact, the 
presence in the CT peptide of solely tyrosine residues as substrate for endogenous kinases 
is insufficient to protect the cells when Ser-129 can also be phosphorylated. 
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Figure 21. CT, a control peptide, demonstrates the beneficial properties of the CTSA peptide. A. 
CT is a peptide corresponding to the C-terminal domain of aSyn and therefore identical to the CTSA 
peptide except without the serine to alanine exchange at residue S129 of the full length aSyn protein 
(see Fig. 7). Cell permeability was tested in OLN WT cells 30 minutes after adding the peptide (5 µM) in 
the media. Cells were fixed and stained for aSyn using ASY-1 antibody (green). Confocal microscopy 
shows staining only in cells treated with the peptide. B. No toxicity was demonstrated in cells treated with 
5µM of CT peptide or vehicle treated controls (CTR) by MTT assay. MTT assay was performed and 
quantified as described in materials and methods section. Bars represent the mean ± S.D C. The effect 
of CT on MT was tested at 5µM by immunofluorescence. CT peptide did not change the MT phenotype 
of cell co-expressing p25 and the aSyn WT, aSyn YF or aSyn SAYF mutants in OLN cells. On the right 
panel cellular degeneration is expressed as percentage of aSyn and p25 transfected cells displaying MT 
retraction. Bars represent the mean ± S.D All data are representative of three independent experiments. 
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4.5.  Effect of tyrosine kinases inhibitors on MT retraction 
 
The results obtained suggested the involvement of aSyn tyrosine phosphorylation in the 
oligodendroglial cellular degeneration and, particularly, its potential protective role. To this 
purpose a former PhD student Louise B. Vesterager at Lundbeck A/S (laboratory of Poul 
Henning Jensen, Biomedicine Department, Aarhus University) characterized the effect of a 
library of kinase inhibitors on the oligodendroglial cell model previously described 246.  A high 
content screening was performed using automated fluorescence microscopy analysis of cells 
co-expressing aSyn and p25 treated and non-treated with the selected library of kinase 
inhibitors. Amongst them 13 different tyrosine kinases inhibitors were able to increase the 
percentage of cells presenting MT retraction and were chosen to be tested in a cell base 
assay. Kinases inhibitors targeting specifically tyrosine kinases and thus modulating aSyn 
tyrosine phosphorylation are expected to increase the MT retraction -due to the abrogation of 
aSyn tyrosine phosphorylation– and the protective mechanism occurring in our OLN model. 
OLN WT cells were transfected with aSyn or aSynSA and p25, treated with the inhibitors 4 
hours post transfection and immunostained 24 h post transfection. We validated in our assay 
three tyrosine kinase inhibitors, for confidentiality purposes named XX, YY and ZZ, as able to 
increase the MT retraction in presence of aSynSA and p25 (Fig. 22). We performed 
immunoblotting analysis to assess the level of phosphorylation on Tyr-125 (only antibody 
commercially available) and aSyn expression levels. Data demonstrated that the inhibitors did 
not affect aSyn expression levels. The levels of phosphorylation on Tyr-125 were not detected 
probably due to a low sensitivity of our assay or the contribution of other tyrosine residues (Fig. 
22A). Immunofluorescence data for one of the kinases validated are shown as example of the 
phenotype observed in presence of the inhibitor (Fig. 22B). 
Overall our results support the hypothesis that tyrosine kinases are involved in aSyn-mediated 
toxicity in a cellular model of MSA but we were unable to demonstrate whether active tyrosine 
kinase inhibitors reduced the phosphorylation of Tyr-125. 
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Figure 22. Tyrosine kinase inhibitors increase Ser-129 phosphorylation-dependent MT retraction 
in an OLN model of MSA. A. On the left panel, cellular degeneration is quantified as percentage of 
aSyn and p25 transfected cells presenting MT retraction in OLN WT cells transiently transfected with 
aSyn + EV (empty vector) or p25, and aSynSA + p25, in the presence (XX or or YY or ZZ) or absence 
(vehicle treatment- DMSO) of a kinase inhibitor. Bars represent the mean ± S.D.  On the central panel, 
OLN WT cells transiently transfected with aSyn + EV (empty vector) or p25, and aSynSA + p25 were 
extracted in RIPA buffer (see materials and methods section) and immunoblotted 24 h post transfection, 
in the presence (XX, YY, ZZ) or absence (DMSO) of a kinase inhibitor, using antibodies against aSyn 
phosphorylated on Tyr-125 and total aSyn. On the right panels, densitometric analyses of the 
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immunodetection of Tyr-125 phosphorylation levels (pTYR125) were normalized for the total amount of 
aSyn (mean ± S.D.). B.  Immunofluorescence of OLN WT cells transiently transfected with aSyn + EV 
(empty vector) or p25, and aSynSA + p25 were 24 h post transfection, in the presence (XX) or absence 
(vehicle treatment-DMSO) of a kinase inhibitor, using antibodies against aSyn (green), p25 (red) and 
tubulin (purple). All data presented are representative of three independent experiments. 
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5. Discussion 
 
The deposition of misfolded aSyn in the form of proteinaceous inclusions is the hallmark of a 
number of related neurodegenerative conditions collectively known as synucleinopathies 487. Within 
these inclusions, aSyn is known to be post-translationally modified. The modifications include 
truncation, oxidation, ubiquitination, and phosphorylation, and are thought to affect the 
conformational and functional state of the protein 316, 319, 344, 375. Interestingly, 90% of aSyn is 
phosphorylated on Ser-129 in LBs 9, while only 5% of aSyn is phosphorylated under physiological 
conditions. Studies conducted until now identified PLK2 and PLK3 as the most efficient kinases 
phosphorylating aSyn 334; data in plk2-/- transgenic mouse showed a strong decrease in aSyn 
phosphorylation on Ser-129 330; and the levels of PLK2 increase in AD and Lewy Body disease 
patients brains 331. What still remains elusive is the actual role of Ser-129 phosphorylation on aSyn 
aggregation and its contribution to the pathogenesis of PD.  
The present study took advantage of established yeast and mammalian cell models to investigate 
the role of Ser-129 phosphorylation in the formation of aSyn inclusions ad toxicity.  PLK2 and PLK3 
were able to phosphorylate aSyn in yeast, but only PLK2 increased aSyn cytotoxicity and the 
formation of intracellular inclusions. Likewise, a kinase dead PLK2 mutant (PLK2DM) -which was 
unable to increase aSyn phosphorylation levels on Ser-129- increased the number of cells 
presenting aSyn foci and cell death, as the active form of the kinase. Additionally, although PLK3 
lead to higher levels of Ser-129 phosphorylation than PLK2; it did not increase aSyn cytotoxicity or 
inclusion formation in yeast. Assessment of the biochemical state of aSyn using ultracentrifugation 
in sucrose gradients revealed an increase in oligomeric species with higher molecular weight, 
when PLK2, PLK2DM or PLK3 were co-expressed. Nonetheless, PLK2 and PLK2DM induced a 
different pattern of distribution of aSyn species, confirming a specific role for PLK2 in aSyn foci 
formation and toxicity in yeast cells. 
Altogether, these data suggest that PLK2 increases aSyn foci formation independently of the levels 
of phosphorylation of aSyn on Ser-129 and that the action of PLK2 on aSyn might involve 
additional effects on targets other than just aSyn, or on other aSyn phosphorylation sites. 
The results obtained in yeast were then validated in human cells. The BiFC assay enabled us to 
investigate the role of PLK2 in a model of aSyn dimerization/oligomerization 488. We observed the 
formation of aSyn cytoplasmic inclusions in cells co-expressing PLK2. Using BI2536, a known 
inhibitor of PLK2 kinase activity, we assessed the role of aSyn Ser-129 phosphorylation on the 
formation of aSyn inclusions. BI2526 reduced aSyn phosphorylation and affected PLK2-mediated 
aSyn inclusion formation.  
To further explore the effect of PLK2 on aSyn misfolding an aggregation model based on the co-
expression of a C-terminally modified form of aSyn (SynT) and synphilin-1 was used in CAD cells 
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13, 183. Results demonstrated that PLK1 was not able to increase the levels of aSyn Ser-129 
phosphorylation but affected the levels of synphilin-1 and may have consequently influenced the 
formation of aSyn larger inclusions. On the other hand, PLK2 was found to significantly increase 
aSyn Ser-129 phosphorylation and inclusion formation, in agreement with the results obtained in 
yeast. As PLK2 does not alter the levels of synphilin-1 and induces the formation of aSyn 
inclusions, these results further imply that the generation of aSyn inclusions requires specific 
factors, further validating the effect of PLK2 in these cellular models of aSyn aggregates formation. 
Despite the ability of PLK3 to increase the phosphorylation levels of aSyn, we could not further 
investigate its role on aSyn aggregation, as it drastically reduced the levels of aSyn, suggesting it 
might promote its degradation. The biochemical nature of the aSyn inclusions formed in the 
presence of PLK2 was also assessed and, in agreement with the data obtained in yeast cells, 
PLK2 caused an overall increase in larger Syn species.  
Here, we provide evidence that PLK2 may be involved in the formation of aSyn aggregates in a 
way that is not solely dependent on its ability to phosphorylate aSyn on Ser-129. Recent studies 
have showed that aSyn may directly impair PLK2 activity and, consequently, inhibit the signaling 
pathway regulated by PLK2, namely p38 MAPK 489. Furthermore, PLK2 has been also involved in 
the inhibition of the mTOR pathway -in a tumor growth context- through the interaction with tubero 
sclerosis complex 1 (TSC1) 490. Interestingly, mTOR pathway is also a known regulator of the 
autophagy degradation system that, together with the ubiquitin-proteasome system, is known to be 
responsible for the clearance of aSyn 386. A very recent paper has proved evidence for the latter 
hypothesis in a rat genetic model over-expressing human aSyn and PLK2. The data demonstrated 
that PLK2 mediated aSyn degradation through both phosphorylation at Ser-129 and formation of a 
protein complex with aSyn 491. These findings demonstrate that PLK2 may influence aSyn turnover, 
but more importantly, the role played by PLK2 expression in aSyn pathobiology as fundamental as 
its capacity to phosphorylate aSyn on Ser-129. This concept as demonstrated by our studies 
obtained combining yeast and mammalian cell models, provide novel experimental support in favor 
of PLK2 as a target for therapeutic intervention in synucleinopathies.  
 
We then performed a functional screening in the yeast Saccharomyces cerevisiae to identify novel 
kinases able to modulate aSyn pathobiology. Yeast has been widely and positively used to 
characterize novel genes involved in the neurodegeneration process 445; therefore it was exploited 
in the present study. Within the yeast kinome, kinases homologous to human ones were identify 
and the most promising ones -based on literature searching and tissue expression- were 
characterized. Two kinases showed a phenotype aSyn dependent: Atg1 and Sky1 decreased 
yeast cell growth; with Sky1 also able to decrease aSyn foci formation. Conversely, they all failed 
to modulate aSyn phosphorylation on Ser-129, although the characterization of other 
phosphorylation sites remains fundamental.  
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The most promising appears to be Atg1, a kinase involved in autophagy, a cellular process whose 
dysfunction has been broadly described in several neurodegenerative disorders 492. Autophagy is 
mainly dependent on nutrient condition; upon induction, by starvation or treatment with rapamycin 
(TOR inhibitor), Atg13 is quickly dephosphorylated, a state that promotes its interaction with Atg1 
initiating the autophagic pathway 493. Importantly, Atg1 is a highly conserved gene, its human 
homologous Ulk1 has been well characterized and it is known to play a similar function to the yeast 
one 494.  
In mammalian cell models Atg1 kinase function is believed to be fundamental in the induction of 
autophagy 495, its over-expression has been used as model to induce autophagy and it has been 
correlated with impaired cell growth and death 483. Interestingly, in our yeast model we detected a 
decrease in cell growth in cells co-expressing aSyn and Atg1, suggesting the dependence of our 
phenotype on aSyn expression. Furhermore, the yeast autophagosome/vacuole system has been 
shown as primarily involved in aSyn clearance 446, supporting our finding on Atg1 contribution. 
Additional experiments will verify if autophagy and aSyn clearing are indeed induced in our model 
since we would expect a decrease in aSyn foci bearing cells, which was not observed. Conversely, 
it was shown that the seeding of larger aggregate in cell lines and primary neuronal cultures 
inhibits aSyn degradation, in particularly impeding autophagosome clearance and increasing cell 
death 496, sustaining also our findings; therefore further data will aim to evaluate aSyn specied 
formed when co-expressed with Atg1 and the effect of Atg1 gene deletion on yeast cells growth.   
In this scenario, Atg1 is a novel potential kinase involved in aSyn pathobiology and may represent 
an additional step toward elucidating the molecular mechanisms of synucleinopathies.  
 
In addition to serine residues, aSyn can be phosphorylated at tyrosine residues Tyr-125, Tyr-133, 
and Tyr-136 in vitro. However, only phosphorylation at Tyr-125 has been detected in vivo 360, 367, 370, 
371. Recent data demonstrated that Tyr-125 phosphorylation diminishes during the normal aging 
process in both humans and flies. Furthermore, in flies’ models of PD Tyr-125 phosphorylation can 
modulate Ser-129 phosphorylation mediated toxicity, suggesting a potential cross-talk between 
these two modifications that may play a central role in aSyn function and may be lost if looking at 
each modification independently. aSynYF mutant flies demonstrated a decreased in climbing ability 
compared with aSyn WT flies; whereas increasing physiologically the levels of Tyr-125 
phosphorylation decreased oligomer formation and rescued aSyn cytotoxicity, suggesting a 
neuroprotective function for Tyr-125 phosphorylation 371.  
Unfortunately, little is known about the functional consequences of tyrosine phosphorylation, and 
whether tyrosine and serine phosphorylation might regulate each other. Thus, to characterize the 
role of tyrosine phosphorylation on aSyn toxicity, we decided to take advantage of an established 
oligodendroglial cell model of MSA. In this model (OLN) co-expression of aSyn and p25 induces 
cell degeneration reflected by microtubule (MT) retraction and activation of apoptosis. Remarkably, 
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this phenotype can be rescue by a non-phosphorylated aSyn at Ser-129 (SA) 246. We therefore 
decided to study the cells displaying MT retraction in presence of several aSyn phosphorylation 
mutants: aSynSA, aSynSAYF and aSynYF. A decrease in MT retraction was evident only in the 
presence of aSynSA, as previously described 246, but also suggesting that tyrosine residues need 
to be available to rescue cell degeneration; and, interestingly, the possibility of a cooperative role 
for Ser-129 and Tyr-123, 133 and 136 in aSyn mediated MT retraction. 
Considering the results obtained, we designed a cell penetrable peptide able to mimic the 
protective mechanism represented by aSynSA mutant. We then produced the CTSA peptide and 
tested in the OLN model. Interestingly, CTSA was able to rescue MT retraction in presence of 
aSyn WT and aSynSAYF, demonstrating that supplementing the intracellular compartment with 
aSyn C-terminal domain inhibits MT retraction. This may be due to a decrease binding of p25 to 
aSyn -indeed p25 promotes aSyn aggregation process 216- or to the activation of signalling 
pathways mediated by the presence of further phosphorylable tyrosine residues. Tyrosine 
phosphorylation is indeed known as a common signalling process that induces cell growth and 
differentiation 497. It was not possible to analyze the effect of CTSA on aSynYF mutant due to the 
low protein expression levels of this mutant; we hypothesized that this mutant generates higher 
insoluble aSyn species that necessitate of different extraction detergent. Additional studies will be 
required to investigate the aSynYF expression behavior. 
We used a control peptide mirroring the C-terminal of aSyn to verify if the effect produced was 
related to the absence of a phosphorylable serine in position 129. Remarkably, this peptide failed 
to reduce MT retraction in all the conditions previously tested. This suggests that adding a peptide 
consisting of the C-terminal part of aSyn is insufficient to promote protection, despite the presence 
of phosphorylable tyrosine residues. Further studies will verify this hypothesis using other peptides 
reproducing the absence of phosphorylable tyrosine (YF) and the absence of phosphorylable Ser-
129 and tyrosine residues (SAYF), respectively.  
Altogether, these data corroborate a protective role for tyrosine phosphorylation in aSyn 
pathobiology, suggesting tyrosine phosphorylation as modulator of aSyn toxicity dependent on the 
phosphorylation status of Ser-129. The tyrosine-phenylalanine mutation is very minor and only 
removes a hydroxyl group from tyrosine; thus it is reasonable to assume that the effect produced is 
due to the absent phosphorylation of the hydroxyl group. 
In parallel, we studied a panel of 13 kinases inhibitors and we validated 5 of them in the OLN 
model here already extensively described 246. The effect of these kinase inhibitors was tested on 
MT retraction, tyrosine phosphorylation and toxicity. All the inhibitors increased MT retraction in 
presence of both aSyn and p25 showing an effect aSyn dependent. We performed immunoblotting 
analysis to characterize if the inhibitors were affecting aSyn expression levels and, most 
importantly, tyrosine 125 phosphorylation levels. The expression levels were unaffected, but 
unfortunately we did not detect any phosphorylation signal; this may be due to a low sensitivity of 
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the assay used or the involvement of other tyrosine residues. It is indeed known that tyrosine 
phosphorylation is an extremely rapid cellular process that may be difficult to characterize by 
classic immunoblotting technique 498. Further studies will confirm this hypothesis adopting 
immunoprecipitation analysis and use of phosphatase inhibitors to stabilize tyrosine 
phosphorylation and thus enhance its detection. 
In summary, these studies corroborate a tight link between tyrosine and serine phosphorylation in 
aSyn misfolding behavior, showing a protective mechanism associated with tyrosine 
phosphorylation and characterizing novel kinases as potential target for therapeutic purposes. 
Furthermore, we identified a cross-talk between Ser-129 and tyrosine phosphorylation sites, 
unraveling the necessity to study in concert these post-translational modifications and 
demonstrating that further experimental approaches have to take in consideration both these 
phosphorylation residues to understand aSyn dysfunction in synucleinopathies and to try to 
eliminate data discrepancies among different model organisms, which might result from differential 
post translational processes. 
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6. General conclusions and future perspectives 
 
Phosphorylation is the main post-translational modification used by any cell type to initiate, 
modulate or turn-off a signaling cascade 499. Phosphorylation modulates protein function and 
activity without the costly necessity of producing new proteins; unfortunately this process is often 
found altered in several human diseases such as neurodegenerative disorders. Here, abnormal 
phosphorylation contributes to protein misfolding, aggregation and ultimately to the pathogenesis 
of the disorder.  
aSyn is amongst those proteins that is anomaly phosphorylated in synucleinopathies, and 
numerous researchers are  trying to understand how this post-translational modification goes awry. 
In this scenario, looking at the kinases and phosphatases responsible for aSyn phosphorylation 
can explain how this modification is acting upon aSyn misfolding behavior opening up new targets 
for therapeutic intervention.   
In this study, we explored the effect of known kinases able to phosphorylate aSyn on Ser-129 on 
toxicity and inclusion formation in established yeast and mammalian cell models, and we 
performed a functional screening in yeast to identify novel kinases involved in aSyn pathobiology. 
Similarly, we characterized the role of tyrosine phosphorylation in terms of toxicity and inclusion 
formation in an oligodendroglial cell model and we assessed novel potential tyrosine kinases 
inhibitors. 
Several studies have substantiated the role of PLK2 in aSyn phosphorylation on Ser-129, but failed 
to understand the link with PD pathogenesis. Our results, combining yeast and mammalian cell 
models, provide novel experimental support in favour of PLK2, but most importantly, demonstrate 
that PLK2 involvement in PD pathogenesis goes beyond its ability to phosphorylate aSyn but 
reside in its mere expression. We showed that PLK2 co-expression induced the formation of more 
inclusions in yeast and larger in cell lines, whose toxicity was proven in yeast but remains to be 
addressed in cells. Remarkably, novel recent studies have pointed to a PLK2-mediated aSyn 
clearance by autophagy, which resulted protective to cells 498. In the light of these results, we can 
hypothize that the step between PLK2 being protective or toxic may reside in aSyn species 
formation, with soluble oligomers more prone to be cleared and larger aggregates leading to cell 
death. Further data are necessary to elucidate which precise PLK2 signaling cascades interfere 
with aSyn inclusion formation in order to implement it as novel therapeutic intervention in 
synucleinopathies. 
Our yeast functional screening allowed the characterization of new kinases involved in aSyn 
pathobiology, extending and corroborating our view on the molecular mechanisms involved in aSyn 
toxicity. Here we provided evidence of Atg1, a fundamental kinase within the autophagy signaling 
cascade, as novel modulator of aSyn pathobiology, unlocking a captivating scenario into the role of 
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aSyn toxicity. Once more autophagy may play a role between the pathogenic and functional state 
of aSyn thus proving fundamental to explore Atg1 involvment in cell models of PD and 
synucleinopathies. 
In this scenario, we also demonstrated that we cannot exclude other aSyn phosphorylation sites 
known to be associated with the pathogenesis of these disorders, to understand aSyn dysfunction. 
In the only work from PD human brain samples; the phosphorylation levels of Tyr-125 decreased 
with age and with Lewy body pathology, corroborating the involvement of Tyr-125 phosphorylation 
in the pathogenesis and, notably, a potential protective role 371. Our investigation validate this 
mechanism: expression of a non-tyrosine phosphorylable version of aSyn (YF) showed increased 
cellular toxicity that could be rescued adding extra tyrosine residues in the form of a peptide 
representing aSyn C-terminal domain non-phosphorylated at Ser-129 reside (CTSA). Although 
additional data will elucidate the molecular mechanism behind the protective function of the CTSA 
peptide; our results demonstrate for the first time the role play by an isolated aSyn C-terminal 
domain on cellular aggregation dependent toxicity. The investigation of tyrosine kinases involved in 
aSyn tyrosine phosphorylation using selective inhibitors, offered further experimental support to our 
findings and the possibility to develop novel therapeutic targets for synucleinopathies. 
The present study establishes crucial lines of investigation on the role of aSyn phosphorylation in 
synucleinopathies and validates the use of different model systems in the study of aSyn 
pathobiology. We validated the implication of Ser-129 phosphorylation in the pathogenesis of the 
disease, a cooperative function between Ser-129 and tyrosine residues and the essential 
involvement of aSyn C-terminal domain in aSyn dysfuntion.  
All in all, uncovering novel targets in the continuous search for new therapeutic treatments will 
enable us to move forward towards the development of more effective therapies for devastating 
disorders of the nervous system, including synucleinopathies, which were the focus of this thesis.  
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